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SUMMARY
By a range of measures, the UK is one of the world’s leading scientific nations, 
both in terms of fundamental and applied research. It is irrefutable that the 
UK’s research excellence was established long before the inception of European 
integration in 1952. As European integration has developed, the UK has 
retained its leading position in the face of growing competition from around 
the world. Against this background, we have sought to examine the relationship 
between the UK’s EU membership and its world-leading capability in science.
The overwhelming balance of opinion made known to this Committee from the 
UK science community valued greatly the UK’s membership of the European 
Union. Science is a major component of the UK’s membership of the EU. 
Nearly one fifth (18.3%) of EU funding to the UK is spent on research and 
development (R&D). In the period 2007–13, EU Framework Programme 7 
funding for science and research in the UK amounted to 3% of the UK’s total 
expenditure on R&D. We heard from universities that this funding is equivalent 
to having another Research Council.
The ease with which talented researchers can move between EU Member 
States and the UK, the EU’s fertile environment for research collaboration, 
harmonised regulations, access to EU research facilities and the availability of 
substantial funding for research combine to make EU membership a highly 
prized feature of the research ecosystem in the UK. Furthermore, the UK plays 
a leading role in the development of EU policies and decision-making processes 
that relate to science and research.
While the UK science community was enthusiastic about EU membership, 
we have uncovered some qualifications. We heard mixed views on the impact 
of EU regulations. The benefits of harmonisation were widely recognised 
but some specific areas, such as genetic modification and clinical trials, were 
highlighted as causing UK business and research to be disadvantaged compared 
to competitors outside the EU.
Many assertions to this inquiry about the UK’s success in winning EU research 
funding conflated performance in securing Framework Programme funds (the 
last being FP7) with the overall level of EU funding for R&D in the UK. The 
UK’s strong science base makes the UK one of the top performing nations in 
the EU where scientific excellence determines success in funding competitions. 
But that is only part of the picture. When the total level of R&D funding is 
considered, the use of structural funds for R&D in less prosperous parts of the 
EU shifts the distribution of funding away from the UK, moving this country 
down the funding league table. It is important to note, however, that Framework 
Programme funds and structural funds serve different purposes.
Many businesses were unwilling to give evidence to our inquiry so our findings 
in this area are based on smaller volumes of evidence than for the academic 
community. Nevertheless, there are indications that, overall, UK businesses are 
less engaged than academics in EU R&D. We have no definitive explanation 
for this pattern, but EU bureaucracy and a relatively low level of support to 
business from the UK Government were cited as parts of the picture.
Access to many research infrastructures is available to non-EU Member States 
in continental Europe as well as to countries outside Europe. We found there to 
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be occasional confusion with regards to which infrastructures are EU-managed 
and which are European in nature. Major research facilities such as CERN, for 
instance, are not part of EU scientific infrastructure, while others, such as the 
ITER nuclear fusion facility, are. Although not a pre-requisite for involvement 
in research infrastructure, EU membership may facilitate influence and provide 
platforms to collaborate.
The scientific advisory system in the EU is in a state of flux as it transitions from 
testing the model of a single Chief Scientific Adviser to the recently created 
Scientific Advice Mechanism (SAM). The SAM is at a formative stage and its 
effectiveness is untested. We are, however, optimistic about its potential. The 
development of the SAM will be critical, as defective scientific advice will lead 
to inadequate policy and legislation being produced at the EU level.
The following chapter sets out our detailed conclusions and recommendations.
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SUMMARY OF CONCLUSIONS AND RECOMMENDATIONS
Regulatory framework
1. We are concerned by the apparent trend towards the development of over-
arching EU regulations. This move away from the use of EU directives may
result in the loss of the flexibility currently afforded to Member States in
transposing directives into national regulations. (Paragraph 18)
2. Despite some EU regulatory frameworks clearly having a detrimental effect
on UK and EU science, we see value in the harmonisation of regulatory
frameworks across Member States. In areas where regulation has had a
negative effect, or the development of new regulations has had the potential to
have such an effect, the UK has often played a key role in working to improve
and formulate more appropriate frameworks. We view the development of the
new clinical trials regulation and data protection regulation to be prominent
examples of this. (Paragraph 39)
Scientific advice and influence
3. We welcome the development of the Scientific Advice Mechanism (SAM)
and the presence of a UK scientist, Professor Dame Julia Slingo, on the
membership of the High Level Group. The SAM, however, is in its infancy
and it remains to be seen how effective and influential it will prove to be.
It is vital that its early promise is fulfilled. The progress of the SAM must
be monitored carefully and we will keep a watching brief in this area, and
trust that others will do the same, not least the UK scientific community.
(Paragraph 55)
4. We conclude that the UK plays a leading role in the development of EU
policies and decision-making processes that relate to science and research.
UK scientists in various EU fora act to ensure that the UK’s voice is clearly
heard and that the EU remains aligned with the advancement of UK science,
particularly by shaping the balance between funding awarded on the basis of
research excellence and that awarded for capacity building. (Paragraph 73)
Funding
5. The EU funding system for science and research is complicated and there
are many ways in which the EU aims to fulfil its shared competence in
research policy. This complexity means that UK researchers can struggle to
navigate through the system. We welcome the efforts made by the European
Commission to reduce the complexity and administrative burden, though
their effectiveness to date is unclear. (Paragraph 102)
6. During the period 2007–13, the UK was a net contributor to the EU overall,
but a net receiver of EU funding for research. Given that just under one fifth
(18.3%) of the funds the UK received from the EU during this time were
used to support science and research, we consider that science is a significant
dimension of the UK’s membership of the EU. (Paragraph 105)
7. Despite many assertions that the UK performs very well in terms of EU
funding for science and research, it has proved challenging to define
unambiguously the level of EU spending on R&D in the UK and how this
compares with other Member States. We have been able to verify the UK’s
position as a high receiver of funds in terms of Framework Programme
funding only. When the portion of the EU’s structural funds designated
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for research and innovation are taken into account, we have found it more 
difficult to assess the UK’s position. (Paragraph 118)
8. The purposes of competitive Framework Programme funds and structural 
funds for research and innovation are different. By designating a portion 
of structural funds for research and innovation, the European Commission 
aims to boost scientific capacity across Member States and increase the 
success rate of applications for competitive Framework Programme funds 
from regions with weaker economies. While we commend this approach, 
we are concerned by the apparent lack of evidence as to whether this 
spending has actually raised the scientific competitiveness of recipients. 
We recommend that this evidence should be assembled by the European 
Commission. (Paragraph 119)
9. We are concerned that the participation of large UK businesses in Framework 
Programme 7 lagged behind that of key competitor nations such as Germany 
and France and was below the EU average. We recognise that participation in 
Horizon 2020 may be greater. However, we remain concerned, particularly 
in the light of the abolition of the Regional Development Agencies (RDAs) 
and introduction of the Local Enterprise Partnerships (LEPs), that UK 
Government support for businesses in engaging with EU funding schemes 
may be weaker than in some other Member States. The integrated approach 
adopted in other countries such as Germany could be viewed as a good 
model and a basis for a programme of benchmarking. For their part, 
however, we urge businesses to engage fully with the opportunities afforded 
by EU funding. We recommend that the UK Government benchmarks its 
level of support for businesses, large and small, wishing to participate in EU 
programmes with that available in other Member States and put forward 
proposals for improving UK performance. (Paragraph 135)
Collaboration
10. It was repeatedly put to us that one of the most significant aspects of the UK’s 
EU membership is the provision of opportunities to collaborate. We view the 
EU to have three main influences: the provision of collaborative funding 
schemes and programmes; ensuring researcher mobility; and facilitating and 
fostering participation in shared pan-European research infrastructures. 
(Paragraph 157)
11. Many would maintain that the provision of collaborative opportunities is 
perhaps the most significant benefit that EU membership affords science and 
research in the UK. These collaborative opportunities are not just between 
Member States but can extend to non-EU and non-European countries. 
(Paragraph 158)
12. The researcher mobility afforded by the EU’s fundamental principle of 
freedom of movement is of critical importance to the UK science community, 
including academia, businesses and charities. It is vital that the flow of 
researchers—both coming to the UK and UK nationals working overseas—
is not restricted. We conclude that researcher mobility must be protected if 
UK science and research is to remain world-leading. (Paragraph 171)
13. Our report on international science, technology, engineering and mathematics 
(STEM) students, published in 2014, highlighted concerns about the negative 
impact of Government immigration policy on international recruitment 
from outside the EU. We are concerned that this situation appears to have 
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changed little since the publication of our report and we recommend that the 
Government reviews its policy in this area. (Paragraph 172)
14. The UK gains significant value from being involved in a number of pan-
European Research Infrastructures (RIs), both as a host country and as a 
user of facilities hosted outside of the UK. We conclude that such European 
based, but non-EU, RIs, although formally independent of the EU, are in 
fact interlinked to varying degrees. (Paragraph 207)
Scenarios
15. The UK might wish to become an Associated Country in the event of Brexit. 
We heard, however, strong views that the UK would lose its influence and 
roles in setting strategic priorities and in decision-making. If Associated 
Country status were to be pursued, further investigation would be required 
in order to ascertain to what extent, and at what expense, the UK’s currently 
influential position would be diminished. (Paragraph 235)
16. Even those who were most in favour of continued membership of the EU—
the university sector—criticised aspects of the UK’s relationship with the 
EU. We therefore conclude that, in the event that the UK chooses to remain 
part of the EU, there would be scope for the UK Government to advance 
reforms to enhance the interactions between the EU and UK science and 
research. We suggest that a particular areas of focus should be the influence 
of the EU on the UK’s regulatory environment and the support available for 
UK businesses in order to facilitate engagement with EU funding schemes. 
(Paragraph 250)

EU membership and UK science
CHAPTER 1: INTRODUCTION
The context for our inquiry
1. During the previous Parliament, the Prime Minister, Rt Hon David Cameron 
MP, pledged that if the Conservative Party won the 2015 general election, he 
would seek to re-negotiate the UK’s relationship with the European Union 
(EU) and then hold an inout referendum on the UK’s continued membership 
by the end of 2017.
2. The UK’s membership of the EU has wide ranging influence on UK science 
and research. The UK’s level of engagement with EU funding programmes, 
for instance, is considerable. EU membership also has significant bearing on 
scientific collaborations, the mobility of researchers, regulatory frameworks 
and research and development (R&D) undertaken by businesses, to highlight 
just some of the interactions between EU membership and the vitality, or 
otherwise, of science and research in the UK.
3. It was against this background of a forthcoming referendum and the scale 
and diversity of EU influence on UK science and research that we decided 
to pursue this inquiry.
4. We have made no attempt at any stage to recommend whether or not the UK 
should remain in the EU—that question is much wider than the scope of this 
inquiry.
The goals of our inquiry
5. Understanding the intricacies of the relationship between EU membership 
and the effectiveness of science and research in the UK is difficult. Its exact 
nature is uncatalogued and the extent of UK-EU interactions is substantial. 
Our inquiry aimed to understand and characterise the principal linkages 
between EU membership and the effectiveness of science and research in 
the UK, acknowledging that there would necessarily be limits to how much 
ground we could cover.
6. Our inquiry did not focus on higher education policy, immigration policy, 
undergraduate student numbers, intellectual property, non-research related 
innovation, or the generality of the single market and business competitiveness. 
We recognise that these issues are of great interest to many people but they 
would have expanded an already wide scope to unmanageable proportions. In 
this report, we use the term ‘science’ broadly to cover research, development 
and applications in all disciplines.
7. We gathered, assimilated and scrutinised evidence from a spectrum of 
practitioners, commentators and campaigners, and we compared and 
contrasted evidence from different sources to identify areas of consensus and 
inconsistency.
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The UK science community and EU membership
8. The evidence we received suggested overwhelming enthusiasm for EU 
membership.1 A number of the organisations that submitted evidence to us 
are mandated to participate in public engagement and education in relation 
to science. We look forward to seeing these organisations interact with the 
general public and promote understanding of the implications of the UK’s 
EU membership for science and research. We take heed, though, of the 
comments of Professor Sir Leszek Borysiewicz, Chair of the Russell Group’s 
EU Advisory Group, and Vice-Chancellor, University of Cambridge, when 
he suggested to us that the relationship between the EU and UK science may 
not be one of the crucial issues considered within the wider population:
“We will make the case, but of all the factors that might influence 
voting, I suspect the impact of the large terrestrial telescope in Chile is 
not going to be the vote-winner in a referendum.”2
Identifying witnesses and evidence
9. We received valuable responses from national academies, professional 
institutions, universities, research institutes, funding bodies, campaign 
groups, Government departments and agencies, scientific advisers and 
individuals with experience of leadership roles in the EU. We also received 
notable contributions from some businesses and charities. We invited further 
contributions from these sectors, but we found businesses, in particular, 
reluctant to submit evidence, perhaps for fear of offending customers or 
shareholders. Overall, the business community was reticent in engaging 
with our inquiry. Many businesses chose not to provide a written submission 
and declined invitations to give oral evidence. Similarly, we were unable to 
attract evidence from many individual medical research charities so cannot 
do justice to their perspective.
10. Our inquiry has naturally been shaped by the specific portfolio of respondents 
and witnesses who have been willing to engage with our investigations. In 
certain areas, the evidence we received is likely to be representative of a larger 
population due to interaction with a range of membership organisations 
who speak for large sectors within the research community. In other areas, 
reflecting thinking accurately has been more challenging. It has been so, 
in particular, with regard to the business community, due both to the lack 
of engagement noted above, and the appearance of differences of opinion 
between the small number of witnesses. It was simply not feasible to hear 
evidence from all business sectors active in research and development in the 
UK.
11. Our Call for Evidence, issued in September 2015, invited answers to 
questions grouped under four themes: regulation, scientific advice, funding 
and collaboration. In the chapters that follow we take each of these themes 
in turn. We conclude by noting some of the scenarios that were put to us 
were the UK to leave the EU, and, in addition, we highlight some issues for 
consideration if the UK chooses to remain in the EU.
12. We repeatedly encountered difficulties on account of the conflation of the 
European Union with the continent of Europe. On occasion, we suspect the 
terms were simply used interchangeably. On other occasions, however, we 
1 Evidence from Scientists for Britain (EUM0075) and Vote Leave (EUM0056) were notable exceptions.
2 Q 64 (Prof Sir Leszek Borysiewicz)
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could not tell whether arguments related to the UK’s EU membership or to 
the UK’s geographical location. We make every effort in the chapters that 
follow to address this important distinction. Equally, we also try to explain 
the differences between EU membership and Associated Country status.
13. We thank everyone who provided written evidence to our inquiry, and all 
those who gave oral evidence in sessions which we held between December 
2015 and March 2016. All the evidence we received is available on our 
website and it provides a rich source of information and opinion which we 
would encourage all those who are interested to view. Finally, we would like 
to thank our specialist adviser, Professor Graeme Reid, Chair of Science and 
Research Policy, University College London, whose expertise was invaluable 
throughout our inquiry.
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CHAPTER 2: REGULATORY FRAMEWORK
14. We begin with the regulatory framework as it sets the broad context in
which UK science and research operate within the EU. The influence of
EU regulatory frameworks on UK science and research is vast and spans
the spectrum of scientific disciplines. As such, our investigations in this area
have been necessarily high-level and heavily influenced by the sectors and
subject areas of those who engaged with our inquiry. We have thus explored
regulation in a general and overall sense and have only considered specific
examples in cases where they were repeatedly highlighted to us.
15. The far-reaching influence of the EU regulatory system was aptly summarised 
by the Campaign for Science and Engineering (CaSE):
“EU-directed regulation affects the UK research environment in diverse 
ways, across the breadth of scientific disciplines, from animal research 
to vacuum cleaner design.”3
The EU regulatory environment
16. The balance of competences4 between the EU and Member States, as set
out in the Treaty of the Functioning of the EU (TFEU), means that a large
number of EU regulatory frameworks influence UK science and research.
These frameworks, termed directives, are constructed at the EU level and it
is then for Member State governments to transpose them into national law.
17. However, it was highlighted to us that there have been moves towards the
development of over-arching EU regulations, as opposed to directives. We
heard from the Wellcome Trust:
“The increasing move away from directives towards regulations within 
EU legislation can reduce the flexibility of Member States to implement 
legislation in a manner conducive to their cultural and ethical research 
environment.”5
18. We are concerned by the apparent trend towards the development of
over-arching EU regulations. This move away from the use of EU
directives may result in the loss of the flexibility currently afforded
to Member States in transposing directives into national regulations.
19. As mentioned previously, a number of EU directives and regulations were
repeatedly highlighted to us. The frameworks brought to our particular
attention included:
• Protection of animals used for scientific purposes directive 2010/63/
EU;
3 Written evidence from the Campaign for Science and Engineering (EUM0047)
4 Competences refer to the balance of powers between the EU and Member States. The EU may only 
act within the limits of the competences conferred upon it by Member States in the Treaties to attain 
the objectives provided therein. Competences not conferred upon the EU in the Treaties remain with 
Member States. The Treaty of Lisbon clarifies the division of competences between the EU and Member 
States. These competences are divided into three main categories: exclusive competences; shared 
competences; and supporting competences. See Division of competences within the European Union: 
EUR-Lex Access to European Union Law, Division of competences within the European Union (January 
2016): http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=URISERV%3Aai0020 [accessed 12 April 
2016]
5 Written evidence from the Wellcome Trust (EUM0034)
13EU MEMBERSHIP AND UK SCIENCE
• Clinical trials directive 2001/20/EC;
• Protection of personal data directive 95/46/EC, soon to be replaced by
a new data protection regulation;
• Deliberate release of GMOs directive 2001/18/EC; and
• Registration, evaluation, authorisation & restriction of chemicals
(REACH) regulations EC 1907/2006.
20. We will briefly consider each of these regulatory frameworks in turn. Again,
we recognise that our analysis is high-level but, due to time and scope
constraints, we could not conduct in-depth investigations.
21. The protection of animals used for scientific purposes directive 2010/63/EU
is the regulatory regime that governs animal research across the EU with the
aim of harmonising animal research standards and practices. The Academy
of Medical Sciences was positive about the influence of this framework and
highlighted the UK’s involvement in its development:
“[the UK science community made] substantial efforts across the sector 
to inform its development and transposition into UK law. A number of 
Fellows noted the leadership shown by the UK on this issue, and the 
wider impact it had on animal welfare across the EU.”6
22. The clinical trials framework 2001/20/EC was drawn to our attention a
number of times as an area of the EU regulatory environment that has not
best served UK science and research. The Association of Medical Research
Charities (AMRC) suggested to us that its implementation had resulted in
an increased administrative burden on researchers as well as an increase in
the cost of running academic trials. They also observed that it has led to a
reduction in the number of global trials taking place in Europe.7
23. Professor Angus Dalgleish, representing Scientists for Britain, conveyed
strong views regarding the clinical trials directive and asserted that its
implementation had resulted in the termination of a successful research
programme that he was involved in.8 He did, however, concede that some
of the problems stemmed from the UK Government’s transposition of the
framework.
24. A new clinical trials regulation has been developed and is expected to come
into effect in 2017. AMRC consider this to be a considerable improvement on
the current clinical trials directive, citing the introduction of a streamlined
applications process and proportionate approach to the monitoring and
safety reporting of clinical trials as key developments. They emphasised the
UK’s role in influencing the evolution of this new regulation:
“The UK health and research community, including AMRC members, 
played an important role in influencing these improvements.”9
25. The regulatory framework for data protection was also mentioned repeatedly
to us. Data protection and copyright affect a variety of areas of scientific
research across a wide spectrum of disciplines. One such area of UK science
6 Written evidence from the Academy of Medical Sciences (EUM0029)
7 Written evidence from AMRC (EUM0052)
8 Q 128 (Prof Angus Dalgleish)
9 Written evidence from AMRC (EUM0052)
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and research that is affected by data protection regulation is medical research. 
Parkinson’s UK provided an explanation of the importance of access to 
patient data for research:
“Personal health records are a valuable resource, revealing the most 
effective ways of caring for patients and allowing us to better understand 
the causes and frequency of conditions.”10
Furthermore, they insisted that ineffective regulation in this area would 
mean that “health and scientific research will be severely threatened.”11
26. A new data protection regulation will replace the protection of personal 
data directive 95/46/EC. If implemented as first drafted, the new regulation 
could have significantly inhibited science and research. Universities UK 
(UUK) suggested that the removal of scientific research from the legitimate 
exemptions for the processing of personal data, as proposed by the European 
Parliament, would have had a substantial negative impact on UK research.12 
The UK science community played an active role in improving the final 
version.
27. During the course of our inquiry the regulatory environment for genetically 
modified organisms (GMOs) was repeatedly highlighted as having had a 
negative impact on UK science and research. This is an area that we are 
familiar with from our previous inquiry on genetically modified insects.13
28. The deliberate release directive 2001/18/EC covers all transgenic GMOs 
including crops and insects. Sense About Science provided a concise 
summary of the problems associated with this regulatory system:
“The regulations are based on an over-statement of the significance 
of this particular plant-breeding process. The assessment system is 
unbalanced. The regulations look only at risks, not at benefits. The end 
point of the European safety assessment process is not governed by any 
kind of scientific measure but by political factors … The expensive and 
complex regulatory system is a barrier to the conduct of research on GM 
[genetically modified] foods in the UK.”14
29. The registration, evaluation, authorisation & restriction of chemicals 
(REACH) regulations were another frequently cited regulatory framework. 
Professor Ric Parker, Director of Research and Technology, Rolls-Royce 
plc and representative of the Royal Academy of Engineering, suggested 
that implementation of this framework had been to the “detriment of the 
competitiveness of some UK companies”.15
30. Felicity Burch, Senior Economist, EEF—The Manufacturers’ Organisation, 
highlighted the impact of REACH on EEF members’ innovation activities:
“We have had a lot of anecdotal evidence from members saying that, 
because they are innovating to respond to REACH, they are not able 
to do as much innovation in other areas as they might like to do, and 
10 Written evidence from Parkinson’s UK (EUM0003)
11 Written evidence from Parkinson’s UK (EUM0003)
12 Written evidence from Universities UK (EUM0054)
13 Science and Technology Committee, Genetically Modified Insects (1st Report, Session 2015–16, HL 
Paper 68)
14 Written evidence from Sense About Science (EUM0073)
15 Q 38 (Prof Ric Parker)
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indeed, we see that more generally with regulation as well. As I have 
said, innovation is extremely resource-intensive and for businesses there 
is only so much you can do, particularly at the smaller end. So I think 
regulations can impact the type of innovation companies do.”16
31. Common to all of the EU regulatory frameworks discussed above is evidence 
of UK influence in mitigating some of the potentially detrimental aspects of 
the frameworks. Dr David Hughes, Global Head of Technology Scouting in 
Syngenta, highlighted this and issued a warning regarding the loss of this 
influence:
“The real key for us [Syngenta] is that, if Britain went its own way in 
Europe, we would lose the most powerful, most influential, significant 
voice pushing for a rational, science-based regulatory system governing 
our technologies. If Britain went its own way, Europe would be in a 
pretty desperate situation, from our point of view. The chances of 
actually achieving a continent-wide, rational, functioning regulatory 
system for our technologies would be distant.”17
32. Some witnesses suggested that problems with the development of EU 
regulation were exacerbated by “interference” in technical matters by the 
European Parliament. Professor Kurt Deketelaere, Secretary-General, 
League of European Research Universities (LERU), was one of the 
proponents of this viewpoint. In reference to the development of the data 
protection regulation he asserted:
“It went completely wrong when a number of people in the European 
Parliament—in a very maniacal way, I must say, because of this 
discussion with the United States on privacy—came up with all kinds of 
amendments changing the text and introducing all kinds of obstacles to 
research. Obviously, at the end of the day the lesson is that perhaps we 
have to elect better people to send to Brussels and to Strasbourg. In that 
case, the problem was not in the European Commission.”18
Harmonisation
33. Although witnesses highlighted several grievances with the EU regulatory 
environment, the majority of evidence suggested that the regulatory 
harmonisation brought about by the EU was of benefit to the UK. Such 
harmonisation can provide a strong platform for collaboration and 
commercialisation in science and research. The Academy of Medical Sciences 
(AMS) corroborated this perspective and suggested that the collaborative 
potential brought about by harmonisation warrants the “burden” of engaging 
with regulatory processes.19
34. The Royal Academy of Engineering noted the value in widely recognised 
standards for businesses and suggested that it is important that the UK plays 
a role in determining them:
“In emerging fields of strategic importance to the UK it is vital to ensure 
first mover advantage in the creation of standards. For UK companies 
16 Q 84 (Felicity Burch)
17 Q 71 (Dr David Hughes)
18 Q 8 (Prof Kurt Deketelaere)
19 Written evidence from the Academy of Medical Sciences (EUM0029)
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to not lose out against international competitors the UK needs to play a 
leadership role in developing international standards.”20
35. Of course, regulatory harmonisation is detrimental when the regulations
being harmonised are ineffective. Dr David Hughes expressed such a
perception in relation to the EU’s regulatory systems that govern agricultural
biotechnologies. He stressed that Syngenta agree with the principle of
regulatory harmonisation but that:
“I think in our particular case the argument is more nuanced, because 
for agricultural technologies—at least, some of them—the regulatory 
systems that are defining those technologies in Europe are not fit 
for purpose. They are non-scientific, scientifically unjustifiable and 
dysfunctional. It is a bit of a mess, quite frankly.”21
36. Juergen Maier, Chief Executive Officer, Siemens UK, indicated that Siemens
view regulatory harmonisation as advantageous. However he outlined the
difficulty often encountered in achieving this harmonisation:
“Of course, regulation and trying to get 28 countries to achieve a 
common standard, whether in electromagnetic field regulation or 
whatever it might be, is going to be difficult, but when you have achieved 
it, it makes processes in design and manufacture a lot simpler.”22
37. The increasingly global nature of science and business means that international 
harmonisation is becoming more relevant. Arguably, moves towards global
harmonisation could override the need for EU-level harmonisation. However,
in this scenario, Professor Siegfried Russwurm told us that the EU acts as
an “aggregator” rather than a “transmitter” and boosts the role of Member
States in the development of global standards.23
38. The opposite of regulatory harmonisation is, of course, the development of
individual national frameworks. The submission from the Royal Society of
Chemistry warned against this and highlighted reservations made by their
members:
“The ability for the UK to set its own regulation was not viewed positively 
due to the perception that businesses would still need to comply with 
EU regulation, as well as any newly-developed UK regulation.”24
39. Despite some EU regulatory frameworks clearly having a detrimental
effect on UK and EU science, we see value in the harmonisation
of regulatory frameworks across Member States. In areas where
regulation has had a negative effect, or the development of new
regulations has had the potential to have such an effect, the UK has
often played a key role in working to improve and formulate more
appropriate frameworks. We view the development of the new clinical
trials regulation and data protection regulation to be prominent
examples of this.
20 Written evidence from the Royal Academy of Engineering (EUM0066)
21 Q 71 (Dr David Hughes)
22 Q 98 (Juergen Maier)
23 Q 101 (Prof Siegfried Russwurm)
24 Written evidence from the Royal Society of Chemistry (EUM0051)
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CHAPTER 3: SCIENTIFIC ADVICE AND INFLUENCE
40. The provision of authoritative scientific advice is central to the formulation
of effective, evidence-based policy. A defective system of scientific advice
will be likely to result in sub-optimal policy-making and legislation. We
therefore sought views on the EU system of scientific advice in order to
determine whether it was appropriate. If the system of EU scientific advice
is inadequate, then it could mean, for example, that the UK is faced with
transposing ill-conceived EU directives into UK law. Moreover, given the
widely admired system of scientific advice in the UK, it would be perverse if
the UK were to suffer at the hands of a less mature EU system.
Scientific advice for EU policy-making
41. The UK has been, and continues to be, a leading voice in the EU striving
for the provision and use of scientific advice. The UK system and the system
that operates within the EU are different. In the UK, there is a Government
Chief Scientific Adviser (GCSA) with responsibility for: providing scientific
advice to the Prime Minister and the Cabinet; advising the Government
on matters of science and technology policy; and ensuring and improving
the quality and use of scientific evidence and advice across government.
The GCSA is also head of the Science and Engineering Profession and is
charged with leading the profession within the Civil Service, encouraging
good practice and ensuring the development of professional skills. The role
of GCSA has existed since 1964.
42. The GCSA is supported by a network of departmental Chief Scientific
Advisers (CSAs). CSAs are a vitally important voice for science and
engineering in the formulation, operation and evaluation of government
policy. They provide independent challenge and seek to ensure that policy
decisions are informed by authoritative science and engineering advice and
evidence.
43. A model somewhat similar to that in operation in the UK was tested in the
EU during the closing years of José Manuel Barroso’s tenure as President
of the European Commission (2004–14). A UK scientist—Professor Dame
Anne Glover—fulfilled the role of Chief Scientific Adviser to the European
Commission. This role, however, was not renewed when President Juncker
assumed the role of European Commission President in 2014. Instead, after
a period of uncertainty, during which widespread concerns were expressed
by the UK science community, a new method of scientific advice, termed
the Scientific Advice Mechanism (SAM), was devised.25
44. The purpose of the SAM is to provide authoritative, timely and independent
scientific advice to the European Commission. The SAM will draw on a
wide range of scientific expertise through close relationships with national
academies and other bodies, as well as the expertise of a High Level
Group of independent scientific advisers. This High Level Group (HLG)
is fundamental to the SAM. Established by a Commission Decision of 16
October 2015,26 the HLG is composed of seven experts, appointed in their
25 European Commission, Scientific Advice Mechanism (March 2016): https://ec.europa.eu/research/sam/
index.cfm [accessed 10 March 2016]. Much of the information that follows is drawn from this source.
26 European Commission, Commission Decision of 16.10.2015 on the setting up of the High Level Group 
of Scientific Advisers C(2015) 6946 final (October 2015): https://ec.europa.eu/research/sam/pdf/c_ 
2015_6946_f1_commission_decision_en_827417.pdf#view=fit&pagemode=none [accessed 10 March 
2016]
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personal capacity, who act independently and in the public interest. The 
group is expected to meet between four to six times per year, but may also be 
convened for additional meetings if urgent advice is required. The HLG will 
designate, on an annual basis, a chairperson and a deputy chairperson. One 
member of the HLG is from the UK, Met Office Chief Scientist, Professor 
Dame Julia Slingo. Dame Julia summarised the HLG’s fundamental purpose 
as follows:
“The Chair of the HLG will represent our views to the Commission; 
they will be the views of the HLG, they will be published and then it is 
up to the Commission to use them in the best way they can.”27
45. Figure 1 below sets out how it is intended that the SAM operates.
Figure 1: Operation of the Scientific Advice Mechanism
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Source: European Commission, About the Scientific Advice Mechanism (November 2015): https://ec.europa.eu/
research/sam/index.cfm?pg=about [accessed 12 April 2016]
46. The SAM secretariat will facilitate the HLG’s access to scientific evidence. 
Crucially, the SAM will have greater staffing and financial resources than 
27 Q 108 (Prof Dame Julia Slingo)
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Professor Dame Anne Glover was equipped with during her tenure at the 
European Commission.
47. It is certainly a positive move that the Joint Research Centre and the SAM 
will be brought together. The European Commission described its plans in 
this area:
“The Joint Research Centre (JRC) has a mission ‘to support EU 
policies with independent evidence throughout the whole policy cycle’. 
It does this through a diversity of science and research-based activities 
to support and advise fellow policy departments in the Commission 
in areas like environment, energy, transport, finance, health, security, 
agriculture and food …
Practical arrangements are being put in place to ensure strong 
complementarities between the independent advice from the SAM and 
the in-house expertise of the Joint Research Centre. To support this 
aim, a number of staff have been seconded into the SAM Secretariat.”28
48. Clare Moody MEP told us that the prospects for the SAM were positive, not 
least because it will be appropriately staffed and integrated:
“While there were considerable concerns about the announcement of the 
abolition of the post of CSA the SAM is better placed to be embedded 
more deeply into the work of the Commission. Firstly SAM is fully 
staffed with a Commission department; it will provide a broader scope 
of scientific input and it is properly integrated into the institutional 
framework of the Commission’s policy development process.”29
49. The UK science community seemed to be broadly optimistic about the 
prospects for the SAM, albeit that it is a body in its infancy and presently it 
is almost certainly the case that “the jury is out.”30 Professor Robin Grimes, 
Chief Scientific Adviser at the Foreign and Commonwealth Office (FCO), 
told us: “I am very positive that this is going in the right direction.”31 Professor 
Alex Halliday, Vice-President, Royal Society, argued that the SAM: “does 
offer some strategic advantages for the UK. Apart from anything else, we have 
Julia Slingo sitting on it as one of the seven members of the Committee.”32 
The Minister of State for Universities and Science, Jo Johnson MP, was also 
positive about the development of the SAM:
“It is good that EU policy-making is going to be informed by the 
best possible scientific evidence. We welcome this direction of travel. 
Commissioner Moedas is taking lots of positive steps in this respect, and 
a lot of his work should be warmly welcomed.”33
50. We harboured some concerns initially, especially about the extent to which 
the HLG would be a purely reactive body. These concerns, however, softened 
as our inquiry progressed. Professor Dame Anne Glover told us that the 
HLG “will absolutely have the ability to identify areas that are not brought 
28 Written evidence from the European Commission (EUM0081)
29 Written evidence from Clare Moody MEP (EUM0062)
30 Q 37 (Prof Sir Robert Lechler)
31 Q 118 (Prof Robin Grimes)
32 Q 37 (Prof Alex Halliday)
33 Q 153 (Jo Johnson MP)
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to them that they identify independently and understand need attention.”34 
Professor Dame Julia Slingo herself reported to us, shortly after the first 
meeting of the SAM on 29 January 2016, that:
“For the bulk of our work we will be tasked by the Commission to provide 
scientific advice based on the work programme of the Commission. We 
also have the opportunity to put forward topics ourselves, and we will do 
so where we believe there is a need for some horizon-scanning or maybe 
a Foresight-type of report on what we believe to be the emerging big 
issues around science for the European Union.”35
51. We sought explicit assurances on this issue and the role of the HLG from the 
European Commission. The Commission told us that the task of the HLG 
is to:
“provide the Commission with independent scientific advice on specific 
policy issues where such advice is critical to the development of EU 
policies or legislation and does not duplicate advice being provided by 
existing bodies and;
support the Commission in identifying specific policy issues where 
independent scientific advice is needed …
The Commission may consult the group at any time on any policy field, 
defining the timespan in which advice is needed and;
The chairperson of the group may advise the Commission to consult the 
group on a specific policy issue.
The SAM HLG may thus advise the Commission on the identification 
of specific policy issues requiring independent scientific advice.”36
52. This offers some reassurance; it is imperative that the HLG is not just a 
creature of the Commission and that it is empowered to identify areas where 
advice is required. And yet, at this very early stage in the SAM’s development, 
it is impossible to foresee how relations will unfold. As the British Academy 
told us:
“It remains to be determined how in practice it [the HLG] will operate 
and what the balance will be between work in response to requests from 
the Commission and ‘own initiative contributions’.”37
53. We are not concerned that the Commission has selected a scientific advice 
model different to the UK model; we accept that there are many ways in 
which the provision of scientific advice might be organised. As Professor 
Dame Anne Glover put it to us: “If you look across the European Union, 
there are 28 Member States and probably about 26 different mechanisms 
for provision of science advice.”38 Professor Robin Grimes informed us that:
“Other countries, Germany and France for example, have different 
structures for carrying out science and a different emphasis on where 
their research is carried out, and as a consequence it is not necessarily 
34 Q 60 (Prof Dame Anne Glover)
35 Q 108 (Prof Dame Julia Slingo)
36 Written evidence from the European Commission (EUM0081)
37 Supplementary written evidence from the British Academy (EUM0076)
38 Q 53 (Prof Dame Anne Glover)
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true that a mechanism like the [UK] chief scientific advisers’ network 
would be appropriate for those countries.”39
54. Whilst it is very welcome that the Commission seems to have made sound 
initial progress with ensuring that it has access to authoritative, independent 
scientific advice, it is certainly not before time. Indeed, it is puzzling that 
the issue of the provision of formal scientific advice has only been taken 
up so recently. Nevertheless, we are greatly encouraged by the eminent 
membership of the HLG, and are particularly pleased to see that a social 
scientist has been appointed. Furthermore, we extend our congratulations to 
Professor Dame Julia Slingo and wish her well on the HLG.
55. We welcome the development of the Scientific Advice Mechanism 
(SAM) and the presence of a UK scientist, Professor Dame Julia 
Slingo, on the membership of the High Level Group. The SAM, 
however, is in its infancy and it remains to be seen how effective 
and influential it will prove to be. It is vital that its early promise is 
fulfilled. The progress of the SAM must be monitored carefully and 
we will keep a watching brief in this area, and trust that others will 
do the same, not least the UK scientific community.
56. In addition to the provision of advice to the Commission, we also briefly 
explored whether the other EU institutions, the European Parliament and 
the Council of the European Union (sometimes still referred to as the 
Council of Ministers) had access to appropriate scientific advice. Professor 
Dame Anne Glover explained to us that:
“At the moment, the Council of Ministers does not have formal science 
advice. What it relies upon is science advice from its own Member State, 
and whatever mechanism that happens to be.”40
57. The European Commission confirmed that:
“There is at present no formal structure which provides scientific advice 
to the Council of the European Union. However, in many Member 
States the Academies and Learned Societies play an important role in 
advising governments and the SAM will also engage these bodies.”41
58. We have given consideration as to whether the remit of the SAM should be 
extended to include the provision of scientific advice to the Council of the 
European Union. With the SAM so newly established and unproven, however, 
it would be unwise to transform its remit at this juncture. Moreover, it seems 
to us to be a perfectly appropriate arrangement that national ministers 
attending the Council draw on their national systems of scientific advice. 
It will be imperative that the SAM engages with Academies and Learned 
Societies across Member States, and as such, can ensure that Member States 
are aware of the SAM’s activities.
59. As regards the provision of science advice in the European Parliament, the 
European Commission explained to us that:
“The European Parliament has a number of formal structures which 
enable Members, committees and other bodies to benefit from scientific 
39 Q 122 (Prof Robin Grimes)
40 Q 53 (Prof Dame Anne Glover)
41 Written evidence from the European Commission (EUM0081)
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advice. These include the Science and Technology Options Assessment 
Panel (STOA). Parliamentary committees may also obtain scientific 
evidence from the Policy Departments, within the Directorates-General 
of committee secretariats for Internal and External Policies, and 
individual MEPs may request briefings from the Members Research 
Service.”42
60. We received evidence suggesting that the environment in the Parliament 
was not necessarily conducive to the sober consideration of scientific advice. 
Stuart Pritchard, EU Affairs Manager, Wellcome Trust, elaborated:
“The Parliament has a number of structures already in place to provide 
advice to members. Whether that advice always cuts through, I am not 
sure, because it is a very noisy environment in the Parliament, with a lot 
of lobbying activity going on and a lot of conflicting advice. For me, one 
of the challenges for parliamentarians is how they find evidence that is 
sufficiently robust to inform discussions when they are being bombarded 
by huge amounts of information. Having some further strengthening 
and rigour in the advice provided to members to counteract that would 
be a helpful addition to the discussions, if it is organised in the right 
way.”43
61. We merely note these observations. Any change or new initiatives in this area 
are a matter for the European Parliament.
UK influence on EU policy for science
62. Throughout our inquiry, it was repeatedly argued that UK scientists have 
considerable influence on EU groupings and decision-making bodies, and 
therefore played a considerable role in shaping EU policy for science.
63. Clare Moody MEP argued that she had “seen first-hand the direct and 
substantial contribution made by UK scientists to EU scientific advice in 
policy making.”44 Professor Paul Boyle, President and Vice-Chancellor, 
University of Leicester, asserted:
“Our voice is very strong in the discussions prior to the decision-making 
around what the different priorities should be. We have had a very 
influential role in helping to shape those decisions.”45
64. Professor Dame Anne Glover told us:
“The UK voice is very welcome, very loud, very credible, and it is acted 
upon [in the EU]. We chair many of the influential committees and, 
regarding identifying members of the council of the European Research 
Council, we have members on that council. We help to deliver policy in 
science funding and where it is spent.”46
Dame Anne added that:
42 Written evidence from the European Commission (EUM0081)
43 Q 109 (Stuart Pritchard)
44 Written evidence from Clare Moody MEP (EUM0062)
45 Q 10 (Prof Paul Boyle)
46 Q 58 (Prof Dame Anne Glover)
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“We have probably more than our fair share of chairs of committees, 
which are opinion-forming. We have a large membership of committees.”47
65. Professor Robin Grimes, Chief Scientific Adviser FCO, reported that:
“We work hard to ensure that the scope of Framework Programmes is in 
line with UK priorities; and because the UK has many world-recognised 
scientists, UK scientists occupy key positions in a range of EU research 
and advisory bodies.”48
66. The European Commission told us that while there is no quantitative 
analysis produced on the UK’s percentage share of committees and positions, 
examples of UK nationals participating in key advisory bodies and expert 
groups, including those where the UK itself proposes the nominations, 
included the following:
“Professor Dame Julia Slingo, Chief Scientist of the UK Met Office, is 
one of the seven member strong high level group for the Commission’s 
new Scientific Advice Mechanism (SAM);
Prof Dame Athene Donald, Professor of Experimental Physics at the 
University of Cambridge, is one of the current 18 members of the 
Scientific Council of the European Research Council;
Sir Leszek Borysiewicz, Vice-Chancellor of the University of Cambridge, 
is the Chair of the ERC [European Research Council] Identification 
Committee for identifying potential new members of the ERC Scientific 
Council;
Dr Claire Craig from the Royal Society is a member of the Governing 
Board of the Joint Research Centre;
Of the 31 in total members of the high level expert group RISE [Research 
and Innovation Staff Exchange] for research, science and innovation, 
five are from the UK or currently working at UK institutions;
46 UK nationals are currently members of Advisory Groups (AGs) 
which provide input for the preparation of the Horizon 2020 work 
programme. This is out of a total of 446, or equal to just over 10%. 
This is the highest number among Member States—Germany has 43. 
The AGs have recently been re-appointed and are just in the process of 
selecting their Chairs;
Richard Fowler Pelly from the UK was one of the 12 member High 
Level Group of experts for the recent ex post evaluation of the Seventh 
Framework Programme;
The UK has been a significant contributor to the work of the European 
Research Area and Innovation Committee (ERAC). The current co-
Chair, David Wilson of the UK Department for Business Innovation 
and Skills (BIS) has been instrumental in preparing the ERA [European 
Research Area] roadmap and the ERA governance document.”49
47 Q 59 (Prof Dame Anne Glover)
48 Q 117 (Prof Robin Grimes)
49 Written evidence from the European Commission (EUM0081)
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67. The UK plays an important role in ensuring that excellence remains 
a key criterion in the allocation of EU funding for science, research and 
innovation and that there is an appropriate balance between funds awarded 
on a competitive basis and those awarded on the basis of capacity building. 
Professor Dame Anne Glover stated that the:
“ERC [European Research Council] funds research purely on the 
basis of excellence of science. The reason that there is such a strong 
commitment to that is through ministerial meetings, where the UK has 
been very active in order to highlight the importance of having a funding 
instrument which is purely based on excellence. The cohesion Member 
States may be less keen to see that it is based on excellence because they 
will have an imperative for capacity building. If there were a Brexit, 
the voice of one of the most important science Member States of the 
European Union would not be there influencing how ERC funding was 
distributed. The top three science Member States are the UK, Germany 
and France, and we do have a very big voice in all things science at EU 
level.”50
68. The European Commission confirmed the UK’s commitment to excellence:
“The UK has been amongst the leaders in terms of support to the key 
policy principles for Horizon 2020 including the defence of excellence 
as the principal criterion for the allocation of funding, the need for 
simplification and greater efficiencies with programme implementation 
including funding models, and the need to ensure open access to 
publications and data generated by EU funded projects.”51
69. Furthermore, the European Commission told us that: “the UK has been 
an active contributor through the Horizon 2020 Programme Committee in 
terms of proposed topics for funding, many of which have been taken up.”52
70. We also heard from Professor Dominic Tildesley, President, Royal Society 
of Chemistry, that “there is a good alignment between the major research 
priorities that you see in Europe and in the UK—for example, research into 
climate change, energy, antimicrobial resistance and healthcare.”53
71. The evidence presented to us clearly argued that the UK plays an influential 
role in the development of EU policies and decision-making relating to 
science and research. We would wish to acknowledge, however, that it is 
difficult to be definitive when assessing influence. Nevertheless, it certainly 
appears that the UK has a strong voice when it comes to putting a firm 
UK imprint on EU policy for science. It would seem hard to agree with the 
view put to us by the Scientists for Britain spokesperson, Professor Angus 
Dalgleish, that “we get drowned out in the EU.”54
72. Interestingly, however, Dame Julia Slingo, did sound a note of caution vis-à-
vis the balance between EU and national priorities:
50 Q 56 (Prof Dame Anne Glover)
51 Written evidence from the European Commission (EUM0081)
52 Written evidence form the European Commission (EUM0081)
53 Q 10 (Prof Dominic Tildesley)
54 Q 129 (Prof Angus Dalgleish)
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“I think we have to be very cautious that our own science agenda and 
our own strategy for science is not taken over too much by what Brussels 
would like to see done …
Because our science base is so strong nationally and we are excellent in a 
number of science areas, we want to be careful not to risk weakening our 
core areas of excellence because we are trying to fit to somebody else’s 
agenda. For me, it is always about getting the right balance between 
national interests and the quality of our science base versus what we 
gain by working more collaboratively in Europe.”55
73. We conclude that the UK plays a leading role in the development of 
EU policies and decision-making processes that relate to science 
and research. UK scientists in various EU fora act to ensure that the 
UK’s voice is clearly heard and that the EU remains aligned with 
the advancement of UK science, particularly by shaping the balance 
between funding awarded on the basis of research excellence and that 
awarded for capacity building.
EU influence on UK international scientific relations
74. Though not a prominent strand of our inquiry, we also heard about the 
international scientific diplomatic opportunities afforded by our membership 
of the EU. The UK’s EU membership has an impact on our participation in 
international fora, including the variety of United Nations’ (UN) bodies that 
have a scientific dimension.
75. Professor Robin Grimes highlighted how EU membership gave the 
UK additional purchase when international scientific issues were under 
discussion:
“There is no formal EU programme called EU Science Diplomacy at the 
moment, but there are areas where our science evidence will underpin 
diplomacy that we have carried out bilaterally and as part of the EU, 
and we are more powerful as a result. A good example of that would be 
climate diplomacy.”56
76. Professor Grimes highlighted the benefits of being able to negotiate as part of 
a bloc and the added value that accrued from being able to draw on bilateral, 
EU and UN approaches:
“I think we gain tremendously from being able to negotiate as part of 
an EU bloc. We were specifically part of that bloc for the negotiations 
for COP21, for example, which gave us considerably more clout, and the 
negotiations were very successful.
However, as I said, we can also have separate negotiations with countries 
and come to bilateral relationships, and we can act through the UN. I 
have no doubt that we will continue to make the most of those three 
areas together, and being part of those three areas gives us a synergy that 
we are able to exploit more readily. We are also able to gain information 
from being part of those three groups and to compare and contrast.”57
55 Q 113 (Prof Dame Julia Slingo)
56 Q 117 (Prof Robin Grimes)
57 Q 118 (Prof Robin Grimes)
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CHAPTER 4: FUNDING
The EU funding system supporting science and research
77. Research policy is a shared competence between the EU and Member States, 
as outlined in the Treaty of the Functioning of the EU (TFEU). Both the 
EU and Member State governments legislate and adopt legally binding acts 
in this area. A number of mechanisms have been established by the EU to 
support science and research. Researchers and organisations within the 28 
Member States (MS) of the EU58 are able to apply and participate in these 
mechanisms. In addition, some non-EU countries are able to participate. 
A total of 13 Associated Countries59 contribute to Framework Programme 
budgets in proportion to their Gross Domestic Product (GDP) which enables 
their researchers and organisations to apply for Horizon 2020 (H2020) 
projects with the same status as those from EU Member States. We return to 
consider Associated Country status in Chapter 6.
78. Furthermore, a number of Third Countries60 participate via individual 
Science and Technology Cooperation Agreements with the EU. This group 
of countries includes the industrialised and emerging economies and several 
developing countries. These countries participate to a lesser extent than 
Member States and Associated Countries.
79. The EU funding system for science, research and innovation is complex. We 
heard a number of times about the bureaucracy that is encountered when 
applying for EU funds or engaging with EU programmes. The submission 
from the Pirbright Institute expressed such concerns:
“The demands of the EU in terms of record keeping are onerous and 
require full original records of every aspect of the costs associated with 
the grant. This level of record keeping seems to be proportionately more 
important than the actual science achieved when reporting back to the 
EU progress and especially in agreeing the final provision of funds to 
support the science.”61
80. We were told that EU grant management can be time-consuming and require 
specialist knowledge. The Wellcome Trust Sanger Institute stated:
“The Grants and Contracts Managers at the Sanger Institute noted 
that EC grants occupied disproportionately more of their time than UK 
grants and that the whole process could be better streamlined.”62
They also commented, however, that the significant benefits from EU grants 
made the extra effort worthwhile.
58 See Appendix 6 for a list of Member States.
59 Thirteen counties have Associated Country status, including Norway, Israel and Switzerland (see 
Appendix 6 for a list of Associated Countries). A bilateral agreement is in place between each country 
and the EU; some are seeking to become EU members while some have chosen not to be.
60 Countries that have signed S&T cooperation agreements with the EU (correct March 2015): 
Argentina, Australia, Brazil, Canada, Chile, China, Egypt, India, Japan, Jordan, Mexico, Morocco, 
New Zealand, Russia, South Africa, South Korea, Tunisia, Ukraine (an Associated Country December 
2015), United States.
61 Written evidence from the Pirbright Institute (EUM0057)
62 Written evidence from the Wellcome Trust Sanger Institute (EUM0030)
27EU MEMBERSHIP AND UK SCIENCE
81. The Royal Society of Biology pointed out that:
“UK Government and EU research funding streams are not readily 
comparable. EU funds are managed across many large scale projects 
and therefore incur increased administrative burden.”63
82. A simplification project has been underway across EU funding schemes in 
order to streamline the processes involved. There was broad consensus that 
efforts being made by the EU to simplify engagement are to be encouraged.
83. The timeframe and recognition of interdisciplinary research within EU 
funding frameworks both received praise. The Association of Medical 
Research Charities (AMRC) suggested:
“It is important that long-term recovery in Europe, including the UK, 
is accompanied by a long-term plan for investment in research and 
innovation. Long-term Framework Programmes offering consistent, 
long-term funding like Horizon 2020 are an important part of this 
picture.”64
84. The University of Cambridge indicated that interdisciplinarity is dealt with 
efficiently within EU funding frameworks:
“The EU research programmes more widely aim to support the inherent 
interdisciplinarity of research—to recognise not only that there are 
global problems which need tackling across geographical borders (the 
challenges posed by an ageing population for example), but also that 
research itself is inherently interdisciplinary.”65
85. In order to inform our investigations, we sought a diagrammatic 
representation of the main ways that the EU supports science and research. 
However, we could not find such a figure, so we have created Figure 2 
below from the evidence we received, European Parliament briefings66 and 
informal discussions with the UK Research Office. This figure attempts to 
capture the principal mechanisms established by the EU to support science 
and research. We are aware that some specific research areas are not shown. 
Environmental research is an illustrative example. In this case, funding can 
be found throughout H2020, particularly the Societal Challenges pillar. A 
number of EU partnerships, including Joint Programming Initiatives (JPIs) 
and Article 185 initiatives, also address environmental issues.
63 Written evidence from the Royal Society of Biology (EUM0068)
64 Written evidence from the Association of Medical Research Charities (EUM0052)
65 Written evidence from University of Cambridge (EUM0049)
66 European Parliament Briefing, Overview of EU Funds for research and innovation (September 2015): 
http://www.europarl.europa.eu/RegData/etudes/BRIE/2015/568327/EPRS_BRI(2015)568327_
EN.pdf [accessed 12 April 2016]
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Figure 2: An attempt to capture the principal mechanisms established by the EU to support science and research
life
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86. The EU supports science and research through five main mechanisms, as 
highlighted in Figure 2, namely:
• The Horizon 2020 programme (formerly the series of Framework 
Programmes 1–7);
• European Structural and Investment funds (ESIF);
• Sectoral research and development programmes;
• Other connected programmes; and
• Partnerships.
87. Some of these programmes involve grants, some are methods of financing 
and others are platforms designed to facilitate collaboration and connections.
Horizon 2020
88. Horizon 2020 (H2020) is the EU’s flagship programme for science and 
innovation. It replaced a series of Framework Programme funds (the last 
being Framework Programme 7) in 2014. It will run from 2014–20 and has 
a budget of approximately €74.8 billion. As shown in Figure 2 above, H2020 
consists of seven main pillars:
(1) Excellent Science, including:
• European Research Council (ERC);
• Marie Skłodowska-Curie actions (MSCA);
• European Research Infrastructures (RIs), including 
e-Infrastructures; and
• Future and Emerging Technologies (FET).
(2) Industrial Leadership, including:
• Leadership in Enabling and Industrial Technologies;
• Innovation in Small-Medium Enterprises (SMEs); and
• Access to risk finance.
(3) Societal Challenges, including:
• Health, Demographic Change and Wellbeing;
• Secure, Clean and Efficient Energy;
• Climate Action, Environment, Resource Efficiency and Raw 
Materials;
• Secure societies—Protecting freedom and security of Europe and 
its citizens;
• Smart, Green and Integrated Transport;
• Europe in a changing world—Inclusive, innovative and reflective 
societies; and
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• Food Security, Sustainable Agriculture and Forestry, Marine, 
Maritime and Inland Water Research and the Bioeconomy.
(4) Spreading Excellence and Widening Participation
(5) Non-nuclear direct actions of the Joint Research Centre (JRC)
(6) European Institute of Innovation and Technology (EIT)
(7) Science with and for Society
89. H2020 is managed by the European Commission’s Directorate-General for 
Research and Innovation (DG RTD). There are seven other DGs with a 
research dimension (Energy, Communication, Agriculture, Education and 
Culture, Growth, Home Affairs and the Joint Research Centre (JRC)) that 
share ownership and responsibility for the Programme with DG RTD.
90. Funding is mostly allocated competitively through calls for proposals to 
which researchers and organisations can apply. Criteria for allocating 
funding vary and include scientific excellence, alignment with a number 
of strategic objectives (grand challenges), geographical and disciplinary 
diversity and potential for commercialisation. European Research Council 
(ERC) funding, part of the Excellent Science pillar, is unique as it is awarded 
solely on the basis of excellence—grants have neither thematic priorities nor 
geographical quotas.
91. Figure 3 below shows EU estimated expenditure on research, development 
and innovation for the period 2014–20, including a breakdown of expenditure 
within Horizon 2020 as well as a breakdown of the Excellent Science pillar of 
Horizon 2020. Funding for other connected programmes and partnerships 
is not included as many of these operate on different timescales and/or are 
funded via aspects of H2020.
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Figure 3: EU estimated expenditure on research, development and 
innovation 2014–20 including a breakdown of expenditure within Horizon 
2020 and a breakdown of the Excellent Science pillar of Horizon 202067
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Structural and Investment Funds
92. Some of the EU’s Structural and Investment Funds (ESIF) are used to 
support research and innovation. Although a large proportion of these funds 
are spent on projects such as building infrastructure, support for research 
and innovation activities is now also one of their priorities. Of the five types 
of ESIF (hereafter referred to as structural funds)—the European Regional 
Development Fund (ERDF), European Social Fund (ESF), Cohesion Fund 
(CF), European Agricultural Fund for Rural Development (EAFRD) and 
European Maritime and Fisheries Fund (EMFF)—only the ERDF and, to 
a lesser extent the ESF, are eligible for funding research and innovation. 
Activities funded include the construction of research infrastructure, 
support for technology transfer and research intensive businesses and skills 
programmes. An estimated €40.2 billion of structural funds will be allocated 
to research and innovation activities over the period 2014–20.68
93. Structural funds are allocated via a different process than that for H2020 
funds. Allocation criteria include GDP per capita and applications from 
individual Member States are also considered. As will be discussed in 
paragraph 112, we have found the topic of structural funds supporting 
science and research to be complex.
67 The sum of the funding as part of the Excellent Science pillar does not exactly correlate to the 
constituent figures due to rounding. 
68 Royal Society, UK research and the European Union: The role of the EU in funding UK research (December 2015): 
https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf [accessed 
12 April 2016]
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94. We heard that synergies between H2020 funds and structural funds for 
research and innovation capacity are being increasingly explored by the 
European Commission. Professor Dame Anne Glover told us:
“On the structural funds, what the Commission has asked all Member 
States to do is to develop a smart specialisation policy. In order to support 
that, they have a smart specialisation panel.”69
95. The European Commission provided us with some clarification on the 
purpose of smart specialisation:
“Smart Specialisation can be defined as ‘place-based approach to 
innovation, rooted on knowledge assets’. In other words it is ‘a strategic 
approach to economic development through targeted support to 
research and innovation’. It gives priority to investments in research 
and innovation activities that play to the regions’ (or country’s) existing 
or potential strengths, and thus ensures a more effective use of public 
funds while stimulating private investment. It focuses on the real growth 
drivers of the country/region.”70
They continued:
“The ultimate goal of smart specialisation is to achieve improved 
innovation ecosystems and a higher impact of the funds.”71
We will return in paragraph 112 to the topic of structural funds for research 
and innovation, and the amount that the UK receives.
Sectoral research and development programmes and other connected programmes
96. Alongside H2020 and structural funds, there are a number of sectoral research 
and development programmes as well as other connected programmes that 
are related to science and research.
97. Sectoral research and development programmes involve space research, 
nuclear energy and coal and steel production. The total research budget for 
these programmes is about €5 billion over the period 2014–20, of which the 
majority (€4.5 billion) is for research into nuclear energy.72 73
98. Other connected programmes include initiatives such as Erasmus Plus (the 
EU’s student exchange programme) and the Enterprise Europe Network 
(EEN). The latter aims to help small and medium-sized enterprises (SMEs) 
make the most of business opportunities in the EU.
99. Also included in other programmes that support science, research and 
innovation is the European Fund for Strategic Investments (EFSI). EFSI is 
a new addition to the system. We are aware of concerns within the science 
69 Q 57 (Prof Dame Anne Glover)
70 Written evidence from the European Commission (EUM0081)
71 Written evidence from the European Commission (EUM0081)
72 Royal Society, UK research and the European Union: The role of the EU in funding UK research (December 2015): 
https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf [accessed 
12 April 2016]
73 These numbers are not exact because these programmes do not all run within the same timeframe.
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community in the UK regarding the repurposing of H2020 funds in order 
to finance EFSI.74
Partnerships
100. The last of the five mechanisms outlined in Figure 2 is partnerships. The EU 
has established a number of strategic partnerships in order to further science 
and research. These include collaborations across Member States such as the 
public-public partnerships termed the Joint Programming Initiatives (JPIs) 
and collaborations across sectors such as the public-private partnerships 
termed the Joint Technology Initiatives (JTIs). A notable example of the 
latter that was brought to our attention is the Innovative Medicines Initiative 
(IMI); the IMI brings together academic researchers and the pharmaceutical 
industry. JTIs receive part funding from H2020 and JPIs are able to apply 
for H2020 funds.
101. A further type of partnership is the so-called Article 185s. These are named 
in reference to a section of the TFEU and are another type of partnership 
that brings together Member States. Again, these are part funded by H2020.
102. The EU funding system for science and research is complicated 
and there are many ways in which the EU aims to fulfil its shared 
competence in research policy. This complexity means that UK 
researchers can struggle to navigate through the system. We 
welcome the efforts made by the European Commission to reduce the 
complexity and administrative burden, though their effectiveness to 
date is unclear.
UK funding for science and research in the EU
103. According to data provided by the Campaign for Science and Engineering 
(CaSE), the Royal Society and others, between 2007 and 2013, the UK 
received €48bn from the EU; of this, €8.8bn was for research, development 
and innovation. Over the same period, the UK contribution to the EU was 
€78bn, of which €5.4bn has been indicated75 as being for the EU’s R&D 
budget.76
104. The UK can be considered as a net contributor to the EU overall, but a net 
receiver of EU funding for science and research. Figure 4 below show the 
flow of funds between the UK and the EU between 2007–13.
74 Horizon 2020 funding was set to be cut by €2.7bn to support EFSI, with no guarantee that the 
equivalent funding would be spent on research and science through EFSI. However, successful 
representations from across Europe ensured the impact of the cuts was reduced, with €500m being 
ring-fenced. Hence, €2.2bn was deducted from the initial Horizon 2020 budget to help fund EFSI.
75 The financial contributions from the UK to EU science and research cannot be determined definitively 
because the UK’s contribution to the EU contains no formally hypothecated amount for research and 
development (R&D). The contribution can, however, be inferred by calculating the proportion of EU 
expenditure devoted to R&D and assuming that the UK contribution includes the same proportion of 
spend.
76 Written evidence from the Campaign for Science and Engineering (EUM0047) and the Royal Society 
(EUM0067)
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Figure 4: Flow of funds between the UK and the EU (2007–13)
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Source: Written evidence from the Campaign for Science and Engineering (EUM0047) and the Royal Society 
(EUM0067)
When these figures are considered, it can be determined that a little under 
one fifth (18.3%) of the funds the UK received from the EU between 2007–
13 was used to support science and research. Clearly, science and research 
are a significant dimension of the UK’s membership of the EU.
105. During the period 2007–13, the UK was a net contributor to the EU 
overall, but a net receiver of EU funding for research. Given that 
just under one fifth (18.3%) of the funds the UK received from the 
EU during this time were used to support science and research, 
we consider that science is a significant dimension of the UK’s 
membership of the EU.
EU funding for science and research in the UK
106. Data on allocations under Framework Programme 7 (FP7), which ran from 
2007–13 as the precursor to H2020, are almost complete and offer a reliable 
indication of comparative performance (in terms of competitive funds for 
research) across Member States. Most respondents to our inquiry quoted 
data from this time period and thus we will do the same.
107. The UK’s comparative performance in terms of funds received for science 
and research varies depending on whether only Framework Programme 
(FP) funds are considered or whether the sum of FP funds and structural 
funds (those designated for research and innovation) is considered. In the 
case of the former, the UK performs very well; both in absolute terms and 
when adjusted on the basis of national GDP.
108. The process by which FP funds are awarded has a high level of transparency 
whereas that which decides the allocation of structural funds for research 
and innovation is less clear. The evidence with regards to excellence-based 
FP funding was consistent; however this was not the case for the evidence 
received in relation to structural funds.
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109. We received data regarding the total EU funds for R&D awarded to Member 
States presented in a variety of ways. These included: total FP7 monetary 
values; FP7 funds normalised for GDP, population and Field-Weighted 
Citation Impact (FWCI);77 the sum of FP7 funds and structural funds for 
research and innovation; and the sum of FP7 funds and structural funds 
normalised according to the factors previously outlined. Figures 5–11 below 
illustrate a variety of ways in which the data can be displayed.78
Figure 5: Total FP7 funds awarded against member states
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016]
77 Field-weighted citation impact divides the number of citations received by a publication by the average 
number of citations received by publications in the same field, of the same type, and published in the 
same year. The world average is indexed to a value of 1.00. Values above 1.00 indicate above-average 
citation impact, and values below 1.00 likewise indicate below-average citation impact.
78 FP7 funds are quoted in billions of euros for the time period 2007–13; structural funds refer to those 
designated for research and innovation and are quoted in billions of euros for the time period 2007–13; 
population data figures relate to 1 January 2015; GDP figures are quoted in euros per capita for the 
time period 2007–13; and FWCI figures relate to 2012.
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Figure 6: Total FP7 funds awarded against member states per unit GDP
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016] and Eurostat Gross domestic product at market prices (2015): http://ec.europa.eu/eurostat/tgm/
refreshTableAction.do?tab=table&plugin=1&pcode=tec00001&language=en [accessed 5 April 2016]
Figure 7: Total FP7 funds awarded against member states per capita
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016] and Eurostat Newsrelease First population estimates (July 2015): http://ec.europa.eu/
eurostat/documents/2995521/6903510/3-10072015-AP-EN.pdf/d2bfb01f-6ac5-4775-8a7e-7b104c1146d0 
[accessed 5 April 2016]
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Figure 8: Total FP7 funds awarded against member states per national 
Field Weighted Citation Impact79
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016] and written evidence from Universities UK (EUM0054)
Figure 9: Total structural funds allocated for research and innovation 
against member states
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016]
79 Field-weighted citation impact divides the number of citations received by a publication by the average 
number of citations received by publications in the same field, of the same type, and published in the 
same year. The world average is indexed to a value of 1.00. Values above 1.00 indicate above-average 
citation impact, and values below 1.00 likewise indicate below-average citation impact.
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Figure 10: Sum of total FP7 funds awarded and total structural funds 
allocated for research and innovation against member states
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[accessed 5 April 2016]
Figure 11: Sum of total FP7 funds awarded and structural funds allocated 
for research and innovation against member states per unit GDP
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016] and Eurostat Gross domestic product at market prices (September 2015): http://ec.europa.
eu/eurostat/tgm/refreshTableAction.do?tab=table&plugin=1&pcode=tec00001&language=en [accessed 5 April 
2016]
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110. Appendix 7 also includes a further presentation of the data as submitted to 
us by the Royal Society.80
111. As can be determined from the Figures above and Appendix 7, the UK’s 
comparative performance in terms of securing EU funds for science and 
research differs depending on whether FP funds or the sum of FP and 
structural funds is considered. We explored structural funds for research 
and innovation in some depth and found this area to be somewhat opaque.
112. Structural funds are awarded based on regional GDP per capita. Regions are 
classified into three categories:81
• Less developed regions (GDP/head < 75% of EU average);
• Transition regions (GDP/head between 75% and 90% of EU average); 
and
• More developed regions (GDP/head >= 90% of EU average).
113. The UK is not positioned to benefit greatly from structural funds. Professor 
Alex Halliday, Vice-President, Royal Society, indicated this and outlined 
some areas in the UK that do receive structural funds:
“Parts of the UK get that funding, such as Cornwall, parts of Scotland 
and parts of Wales, where there has been a need for investment, and 
the European Union has been providing some of that funding for 
infrastructure. However, the scale of what is needed in the UK compared 
with what is needed in some of the other countries in the European 
Union is not the same at all.”82
114. Dr Mike Galsworthy, Programme Director of Scientists for EU, argued that 
FP funds and structural funds should be considered separately. He suggested 
to us that the awarding of these funds to less scientifically developed nations 
increases research capacity and thus provides an increased number of 
facilities and skilled researchers for the UK to collaborate with and benefit 
from. He said:
“By conflating the two, you merely look at the finances of it rather than 
the value of the whole system, and I believe the value of the whole system 
is clearly beneficial because it is well structured.”83
115. Professor Sir Leszek Borysiewicz, Chair of the Russell Group’s EU 
Advisory Group, and Vice-Chancellor, University of Cambridge, succinctly 
highlighted the fundamental dichotomy that this area presents:
“This is a major topic within the European Union that goes to the heart 
of that debate—the competitiveness issue as opposed to the level playing 
field issue. These are two fundamental principles, and this particular 
80 Royal Society, UK research and the European Union: The role of the EU in funding UK research (December 2015): 
https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf [accessed 
5 April 2016]
81 European Commission, Structural Funds (ERDF and ESF) eligibility 2014–2020: http://ec.europa.eu/
regional_policy/sources/what/future/img/eligibility20142020.pdf [accessed 12 April 2016]
82 Q 26 (Prof Alex Halliday)
83 Q 129 (Dr Mike Galsworthy)
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theme often finds itself involved in a contretemps between those two 
ideals that Europe proposes.”84
116. The purpose of the designation of a portion of structural funds for research 
and innovation projects is to elevate the broader science capacity and 
capability across Member States. The Minister of State for Universities and 
Science, Jo Johnson MP, told us:
“structural funds are about helping disadvantaged, more deprived areas 
of the European Union to develop the capabilities to be competitive and 
eventually to be in a position where they are capable of competing for 
the science streams of money.”85
117. It is expected that Member States with lower scientific capacity and 
capabilities will utilise structural funds in such a way that it will enable them 
to be more successful in applying for FP funds, i.e. funds based on scientific 
excellence. Jo Johnson MP, however, was unable to confirm to us whether any 
assessment had been done so far at Commission level in order to determine 
if the use of structural funds in this way has been effective.86 There appears 
to be no evidence that the awarding of structural funds for research and 
innovation has resulted in an improved success rate, or increased application 
rate, to FP7 or H2020.
118. Despite many assertions that the UK performs very well in terms of 
EU funding for science and research, it has proved challenging to 
define unambiguously the level of EU spending on R&D in the UK 
and how this compares with other Member States. We have been 
able to verify the UK’s position as a high receiver of funds in terms 
of Framework Programme funding only. When the portion of the 
EU’s structural funds designated for research and innovation are 
taken into account, we have found it more difficult to assess the UK’s 
position.
119. The purposes of competitive Framework Programme funds and 
structural funds for research and innovation are different. By 
designating a portion of structural funds for research and innovation, 
the European Commission aims to boost scientific capacity across 
Member States and increase the success rate of applications for 
competitive Framework Programme funds from regions with weaker 
economies. While we commend this approach, we are concerned by 
the apparent lack of evidence as to whether this spending has actually 
raised the scientific competitiveness of recipients. We recommend 
that this evidence should be assembled by the European Commission.
120. The UK is the top performer across Member States in terms of securing 
European Research Council (ERC) funding, i.e. funding awarded solely 
on the basis of excellence. Professor Dame Helen Wallace, representing 
the British Academy, highlighted that the humanities and social science 
community in particular benefit disproportionately well from this part of the 
Excellent Science pillar of H2020.87
84 Q 65 (Prof Sir Leszek Borysiewicz)
85 Q 144 (Jo Johnson MP)
86 Q 145 (Jo Johnson MP)
87 Q 42 (Prof Dame Helen Wallace)
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121. Professor Sir Mark Walport, Government Chief Scientific Adviser, said of 
ERC funding:
“The European Research Council in its existing form recognises to a 
significant extent the emphasis of the UK and some other countries in 
Europe on supporting the brightest and the best.”88
122. Figures 12 and 13 below show the amount of FP7 funding awarded to the 
UK per sector alongside UK expenditure on R&D by source of funding.
Figure 12: FP7 funding awarded to UK by sector (2007–13)
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 5 April 2016]
Figure 13: UK expenditure on R&D by source of funding (2007–13)
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Source: Royal Society, UK research and the European Union: The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
88 Q 156 (Prof Sir Mark Walport)
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[accessed 5 April 2016]
123. As can be determined from Figure 12, the university sector was the largest 
recipient of FP7 funding for science and research in the UK between 2007 
and 2013. Figure 13 shows that, in the same time period, FP7 funding 
amounted to 3% of the UK’s total expenditure on R&D. We heard from 
universities that this funding is equivalent to having another Research 
Council.89
124. In the UK, 64% of research and development is conducted by businesses,90 
yet businesses attracted just 18% of the total funds awarded to the UK 
through FP7. This is below the EU average and much lower than countries 
such as Germany and France. We return to this this issue in the next section 
of this chapter.
125. We received submissions from a number of research institutes, organisations 
and laboratories that emphasised the importance of EU funding to their 
research portfolios. Submissions from the Wellcome Trust Sanger Institute, 
the National Physical Laboratory (NPL), the John Innes Centre, the Centre 
for Ecology and Hydrology (CEH) and the Met Office emphasised the 
importance of EU funding streams and cited the financial contributions 
from EU-level funding programmes to their operations.91
Business and innovation
126. As previously mentioned, 64% of R&D in the UK is conducted by businesses 
yet this sector attracted just 18% of the total funds awarded to the UK 
through FP7. Figure 14 below shows a comparison between FP7 funding 
awarded to businesses in the UK and in key competitor nations Germany 
and France, alongside the EU average.
89 Q 63 (Prof Sir Leszek Borysiewicz)
90 Office for National Statistics, UK Gross Domestic Expenditure on Research and Development, 2013 
(March 2015): http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/
ons/dcp171778_398876.pdf [accessed 12 April 2016]
91 Written evidence from the Wellcome Trust Sanger Institute (EUM0030), the National Physical 
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Figure 14: Percentage of FP7 funding awarded to businesses in the UK 
and key competitor nations (2007–13)
Germany
France
UK
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EU Average
Source: Written evidence from the Royal Society (EUM0067)
127. Participation of UK businesses in FP7 was below that of Germany and France 
and also below that of the EU average. However, this low participation was 
not uniform across the spectrum of UK business. The Royal Academy of 
Engineering highlighted UK SME participation to us:
“Interestingly, SMEs accounted for 13.7% of the UK’s total FP7 budget 
share, which is greater than France at 11.94% and similar to Germany 
at 13.54%.”92
It appears that it is large businesses that are particularly underrepresented in 
the UK’s EU funded research and innovation portfolio.
128. Dr David Hughes, Global Head of Technology Scouting, Syngenta, offered 
a view from a large business:
“My impression is that Horizon 2020 was not really designed with big 
companies in mind. I think it was designed to encourage collaboration, 
primarily in the private sector, with small and medium-sized enterprises.”93
129. We explored the difference between the participation of large businesses in 
Germany and the UK with Professor Siegfried Russwurm, Chief Technology 
Officer & Member of the Managing Board of Siemens AG. Professor 
Russwurm suggested that there are a number of cultural differences between 
the two countries that could account for the difference. He proposed that UK 
businesses are traditionally more self-sustaining while German businesses 
interact more closely with Governments and intergovernmental institutions. 
He suggested that there is considerable expertise in Germany in dealing with 
business-Government interactions and that there are a number of supportive 
industrial associations. 94
130. It was also suggested that one of the reasons that UK business participation 
is low is due to inadequate support from the UK Government for applying 
92 Written evidence from the Royal Academy of Engineering (EUM0066)
93 Q 70 (Dr David Hughes)
94 Q 94 (Prof Siegfried Russwurm)
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for funds. Support was previously provided by the, now disbanded, Regional 
Development Agencies (RDAs). Responsibility lies with the Local Enterprise 
Partnerships (LEPs) and Innovate UK. Professor Ric Parker raised concerns 
with regards to this change in the support system for businesses:
“The RDAs, through their innovation funds and their innovation 
boards, did a lot to stimulate engagement in Europe from the business 
community. The LEPs that have replaced them no longer have that 
prime objective and the funding to achieve that, so we are seeing less 
stimulation of UK industry to engage in the European programmes, 
which is regrettable.”95
131. While we do not view the support previously provided by the RDAs as 
necessarily optimal, we recognise that it may have deteriorated with the 
advent of the LEPs. Professor Parker highlighted the role that Innovate UK 
has to play:
“It is part of the formal remit of Innovate UK, if you look at their charter, 
to help in this way. Again, that is very London-centric and tends to be a 
website people can go to and it really needs to spill out into the regions 
a bit more.”96
132. We are aware that changes made to H2020, in light of business interaction 
with FP7, to facilitate business interaction have been welcomed by some. 
The submission from EEF—the Manufacturers’ Organisation, suggested 
that UK business participation in H2020 was proving more successful:
“The programme is deliberately more geared towards industry, and this 
is paying off. The proportion of funding going to the private sector has 
increased from 24% to about 28%. A large share of this has gone to 
SMEs. In particular, the new SME instrument is benefiting smaller UK 
companies.”97
133. Syngenta, however, remain reluctant to engage with H2020 projects. They 
outlined the reasoning behind this as:
“the number of administrative processes that must be adhered to 
along with the unacceptable requirements surrounding any intellectual 
property generated through these projects. Therefore, as a company, we 
are unlikely to ever lead a Horizon 2020 bid and would only consider 
engaging in any Horizon 2020 projects where the intellectual property 
considerations made commercial sense.”98
They highlighted further misgivings about the H2020 scheme:
“Additionally, we believe the primary focus of the Horizon 2020 funding 
is misdirected. Often the questions being asked are very narrow, too 
focused and consequently fail to look at the bigger picture and address the 
fundamental issues. Looking at details in isolation without investigating 
how this then impacts the problem as a whole can lead to all sorts of 
poorly structured and inaccurate conclusions being drawn.”99
95 Q 32 (Prof Ric Parker)
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134. As alluded to previously, we did not receive sufficient evidence to make 
statements across the entire spectrum of sectors within the business 
community. However, from the range of evidence that we did receive, we 
discovered that the relevance of H2020 and EU schemes in general varies 
between industry sectors. We heard from Steve Bates, Chief Executive 
Officer, BioIndustry Association, that Horizon 2020 may arguably be 
working better in biomedicine than in the agro-industry area.100
135. We are concerned that the participation of large UK businesses in 
Framework Programme 7 lagged behind that of key competitor nations 
such as Germany and France and was below the EU average. We 
recognise that participation in Horizon 2020 may be greater. However, 
we remain concerned, particularly in the light of the abolition of the 
Regional Development Agencies (RDAs) and introduction of the 
Local Enterprise Partnerships (LEPs), that UK Government support 
for businesses in engaging with EU funding schemes may be weaker 
than in some other Member States. The integrated approach adopted 
in other countries such as Germany could be viewed as a good model 
and a basis for a programme of benchmarking. For their part, 
however, we urge businesses to engage fully with the opportunities 
afforded by EU funding. We recommend that the UK Government 
benchmarks its level of support for businesses, large and small, 
wishing to participate in EU programmes with that available in 
other Member States and put forward proposals for improving UK 
performance.
100 Q 70 (Steve Bates)
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CHAPTER 5: COLLABORATION
136. Twenty-first century science does not recognise national boundaries; it is a 
global endeavour. No single country can act alone to address the challenges 
and threats facing society today. When modern-day scientific endeavours 
are considered as a whole, we agree with the two key trends identified by Dr 
David Hughes, Global Head of Technology Scouting, Syngenta:
“The first one is convergence, which is the blurring of scientific 
boundaries. The second is internationalisation.”101
137. Interdisciplinarity was touched on as part of our discussion of the EU’s 
funding system for science and research in Chapter 4, and we will now focus 
on the internationalisation of science and the necessary collaboration this 
involves.
138. Concomitant with the evolution of this trend towards internationalisation has 
been the rise of ‘big science’; that is, science performed on an increasingly 
large scale. We heard that while the USA was the pioneer initially, other 
countries have caught up. Professor Steve Cowley, Chief Executive of the 
UK Atomic Energy Authority (UKAEA) and Head of the EURATOM/
Culham Centre for Fusion Energy (CCFE), told us:
“In the years since the early 1980s, Europe has become the world 
leader in big science. More and more science is progressing towards big 
science.”102
139. The importance of scientific collaboration to the productivity and vitality of 
UK science and research was repeatedly highlighted. Indeed, it was perhaps 
the only area we explored where there was almost complete agreement. The 
submission from the Government identified the UK’s top collaborative 
partners during 2008–12 as the United States, Germany, France, Italy, and 
Australia.103
140. Collaboration is vital across the spectrum of scientific disciples. However, 
its importance in the medical research sector was said to be particularly 
important. The Association of Medical Research Charities asserted:
“In some instances, collaborative research is vital. For example in 
the case of rare cancers it is often necessary to recruit patients from 
multiple countries in order to conduct trials with sufficient numbers of 
participants.”104
141. We received substantial evidence about the role that EU membership plays 
in facilitating collaboration. A number of times however, EU and European 
collaboration were conflated. We view the role of the EU in this respect to be 
tripartite in nature involving:
• The provision of collaborative funding schemes and programmes;
• The researcher mobility afforded by the requirement for freedom of 
movement; and
101 Q 74 (Dr David Hughes)
102 Q 2 (Prof Steve Cowley)
103 Written evidence from HM Government (EUM0071)
104 Written evidence from the Association of Medical Research Charities (EUM0052)
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• The facilitating and fostering of participation in shared European 
research infrastructures.
142. Professor Dame Janet Thornton told us of the function of EU funding for 
science and research in terms of building collaborations: “EU grants serve 
to form the collaborative umbrella that joins together that nation state 
funding.”105
143. The Government also emphasised the value of EU schemes over and above 
national funding programmes:
“EU programmes and initiatives provide access to opportunities and 
co-operation on science and research that are often difficult to provide 
at national level, either because they are too costly (nuclear fusion, for 
example) or because the sample size in any one country is so small (rare 
diseases, for example).”106
144. We heard about how a supranational framework, like that provided by the 
EU, can simplify collaborations when compared to reliance on bilateral or 
multilateral agreements. Funding schemes that span Member States enable 
multinational collaborations that may not be possible with only national 
sources of funding—due to the complexities of aligning funding sources, 
timeframes and arranging a number of bilateral/multilateral agreements etc. 
Professor Dame Julia Goodfellow, President, Universities UK (UUK), was 
among those who stressed the importance of this aspect of EU funding:
“this is money for cross-country collaboration so, from that point of 
view, it is very important and perhaps unique in some way.”107
145. As outlined in Chapter 4, many EU funding schemes and programmes 
require or encourage collaboration—both between researchers in different 
Member States and between those in academia and industry. A number of 
submissions presented case studies of projects, programmes and organisations 
where EU involvement had been crucial. Individual details of these have not 
been included in this report but they represent a valuable resource and can 
be found in the written evidence.108
146. The EU aspires to the creation of a European Research Area (ERA) to 
capitalise on cross-continental collaboration and ensure maximum impact 
of resources. The Royal Society provided some explanation of the ERA:
“This is intended to be: ‘a unified research area open to the world based 
on the Internal Market, in which researchers, scientific knowledge 
and technology circulate freely and through which the Union and its 
Member States strengthen their scientific and technological bases, 
their competitiveness and their capacity to collectively address grand 
challenges.’”109
105 Q 2 (Prof Dame Janet Thornton)
106 Written evidence from HM Government (EUM0071)
107 Q 63 (Prof Dame Julia Goodfellow)
108 The following submissions highlighted case studies: ISARIC and ERGO at the Centre for Tropical 
Medicine and Global Health, University of Oxford (EUM0041); Europlanet Consortium (EUM0045); 
National Physical Laboratory (EUM0025); the UK Atomic Energy Authority (EUM0024); the 
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147. There is no formal membership of the ERA; it represents a conceptual 
network rather than a tangible zone. The European Research Area and 
Innovation Committee (ERAC) monitors the ERA and comprises the 
Commission and Member States, with Associated Countries as observers. 
As part of the ERA the Commission also has partnership agreements with a 
number of representative bodies, such as Science Europe and the League of 
European Research Universities (LERU).
148. Collaboration, particularly the role that EU membership plays, is hard to 
quantify. It is very difficult to ascertain whether the UK’s collaborative 
relationships would have developed in the same way without EU membership. 
Minister of State for Universities and Science, Jo Johnson MP, told us that:
“I think it is undeniable that we were a big player in science long before 
the European Union came into existence. Many of our great universities 
have been around and were successful as centres of learning long before 
even the countries that are now part of the European Union came into 
existence”110
149. David Walker, Head of Policy at the Academy of Social Sciences, urged 
caution in over-emphasising the role of EU membership. He pointed out the 
complexity encountered in attempting to determine how collaborations were 
instigated:
“There is a rich pattern of exchanges, but pinning responsibility for those 
to the European Union and its programmes is much more difficult.”111
150. Professor Sir Leszek Borysiewicz highlighted the importance of attempting 
to quantify collaboration and presented some analysis:
“If you take UK participation in that programme [Framework 
Programme 7, 2007–13], 100,000 collaborative links were established as 
a consequence; 18,500 of those were with Germany; France was second 
with nearly 13,000, and then Italy with 12,000. Consequential on those 
Framework Programme 7 links, 10,000 of those links were made within 
the UK.”112
151. We also explored the relationship between EU membership and the 
development of non-EU and non-European collaborations. We considered 
suggestions that collaborative EU schemes can attract and facilitate 
interactions with non-European countries. Conversely, we also investigated 
concerns that the focus of the EU, and stipulation in some cases, on EU 
Member State and Associated Country collaborations can inhibit interactions 
with non-European countries.
152.  Technopolis suggested that EU membership does not prohibit non-EU 
collaborations:
“it [the EU] provides a framework that is often more attractive than 
inter-governmental agreements. The EU does not have legal competence 
over science policy in the Member States and there is nothing to prevent 
110 Q 147 (Jo Johnson MP)
111 Q 42 (David Walker)
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them [EU countries and non-EU countries] from working together 
outside of the EU framework in whichever way they choose.”113
153. On international, non-EU collaboration and whether there is an ‘opportunity 
cost’ for Member States associated with having to collaborate with EU 
Member States, Dr Mike Galsworthy, Programme Director for Scientists for 
EU, argued the contrary. He described the EU as a “catalyst for our capacity 
to reach around the globe”.114 He elaborated on Horizon 2020 and non-EU/
non-European participation as follows:
“The size of the programme means that it is comprehensive in subject 
areas and well-known as a brand—ensuring a certain quality—and 
therefore, should other countries, such as the US, want to collaborate 
with the UK, there is a huge channel of potential for doing that through 
the EU programme, because of all these factors and because you can 
bring in other partners.”115
154. As alluded to by Dr Galsworthy, the EU has international agreements for 
scientific and technological co-operation with 20 countries. These create 
a framework for participation in joint projects, sharing of facilities, staff 
exchanges or the organisation of specific events.
155. Professor Robin Grimes, Chief Scientific Adviser, Foreign and 
Commonwealth Office, cited an example of the role of the UK’s EU 
membership in facilitating interactions with a non-EU, non-European 
country. On UK-Chinese scientific interactions, he told us:
“We work with the EU in China to maximise our policy impact and 
our influence in China to make changes to the enabling framework, 
which allows better conditions for UK-China collaboration, including 
on intellectual property protection, for example, where we align our 
lobbying with the EU and use the EU-China dialogue to push forward 
on that sort of difficult issue. Again, we come back to the point that 
it [EU membership] really complements our bilateral activities in this 
regard.”116
156. UKspace also suggested a positive role for EU membership in facilitating 
international connections:
“One of the benefits of Britain’s EU membership is that non-EU 
organisations (from USA, Japan, etc.) often find UK organisations 
attractive for collaboration because of our EU membership.”117
157. It was repeatedly put to us that one of the most significant aspects of the 
UK’s EU membership is the provision of opportunities to collaborate. 
We view the EU to have three main influences: the provision of 
collaborative funding schemes and programmes; ensuring researcher 
mobility; and facilitating and fostering participation in shared pan-
European research infrastructures.
113 Written evidence from Technopolis (EUM0037)
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158. Many would maintain that the provision of collaborative opportunities 
is perhaps the most significant benefit that EU membership affords 
science and research in the UK. These collaborative opportunities 
are not just between Member States but can extend to non-EU and 
non-European countries.
Researcher mobility
159. Freedom of movement is a fundamental principle of the EU enshrined in 
Article 45 of the Treaty of the Functioning of the EU (TFEU). This entitles 
EU citizens to:
• Look for a job in another EU country;
• Work there without requiring a work permit;
• Reside there for that purpose;
• Stay there even after employment has finished; and
• Enjoy equal treatment with nationals in access to employment, working 
conditions and all other social and tax advantages. 118
160. Free movement of workers also applies, in general terms, to countries in 
the European Economic Area (EEA): Iceland, Liechtenstein and Norway. 
There is also a bilateral agreement in place with Switzerland.
161. In the context of science and research, freedom of movement enables mobility 
of researchers/students and simplifies the recruitment of scientists from EU 
Member States and the EEA (plus Switzerland) to the UK. There was a 
very strong consensus in the evidence we received from across the science 
community—academia, industry and charities—of the value of researcher 
mobility afforded by freedom of movement.
162. We heard particularly strong assertions from the UK higher education 
(HE) sector. Professor Sir Peter Downes, Convenor of Universities Scotland 
and Principal & Vice-Chancellor, University of Dundee, offered one such 
opinion:
“The principle of freedom of movement of people is not only one of 
the most important principles of the EU but one of the most important 
benefits of EU membership to higher education in the UK.”119
163. Professor Sir Mark Walport, Government Chief Scientific Adviser, also 
highlighted its importance and provided some quantification:
“At the moment, 30% of European Research Council grantees working 
in the UK come from other Member States; and 15% of UK academic 
staff are from continental Europe, which compares with 11% of the whole 
of non-EU, so not only the funding but the people are very important.”120
164. The business community emphasised the positive impact that researcher 
mobility has on their ability to recruit the most talented staff. Professor Ric 
Parker, Director of Research and Technology, Rolls-Royce plc, representing 
118 European Commission, Employment, Social Affairs and Inclusion: Free Movement—EU nationals: http://
ec.europa.eu/social/main.jsp?catId=457 [accessed 12 April 2016]
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the Royal Academy of Engineering, highlighted the value of the EU’s 
principle of freedom of movement to Rolls-Royce plc, citing how it enables 
easy movement of employees across the company’s multiple European sites.121
165.  A number of EU schemes enable researcher and student mobility across 
the Europe including the Marie Skłodowska-Curie actions (MSCA) and 
Erasmus Plus schemes (see Chapter 4, Figure 2 for how these schemes fit 
into the EU environment that supports science and research). These schemes 
were frequently praised.122
166. Movement of researchers and students in two directions is vital. This enables 
both talented individuals to enter the UK as well as allowing UK citizens 
to develop specialised skills and knowledge overseas. Professor Andrew 
Harrison, Chief Executive, Diamond Light Source, suggested this as a 
reason for the excellence within the UK science community:
“The reason why many UK scientists are as trained and skilled as they 
are is that they have also gone abroad.”123
167. A corollary of the ease of researcher mobility within the EU and EEA (plus 
Switzerland) could be that international, non-European researchers are put 
at a disadvantage. However, we did not receive substantial evidence of such 
a disadvantage. Instead, we consider that it is the UK’s own immigration 
policy, rather than the ease of researcher mobility within the EU and EEA 
(plus Switzerland), that underlies any disadvantage to non-European 
researchers. Although outside the scope of our inquiry, we heard a number 
of concerns about the current visa system for the recruitment of non-EU 
researchers and students.124
168. The prospect of a restriction in researcher mobility has sparked wide concern 
across the science and research community. The submission from Syngenta 
highlighted a perspective from large business:
“[if] restrictions were placed on recruitment from the EU then 
Syngenta’s ability to employ the best talent and scientific minds would be 
compromised. This would not only impact our ability to remain as one 
of Syngenta’s leading R&D sites but would also hinder the professional 
development of our UK scientists due to reduced interactions.”125
169. Professor Siegfried Russwurm, Chief Technology Officer & Member of the 
Managing Board of Siemens AG, shared these concerns and presented an 
example to us of how Siemens reacted when researcher mobility was curtailed 
in South Africa:
“The South African Government have greatly tightened the inflow of 
qualified workers, with the result that as this expertise is not available 
on the labour market in South Africa, we [Siemens] have reduced our 
activities and refrained from offering some of our Siemens systems 
because, frankly, we do not have the qualified experts.”126
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170. Restriction of researcher mobility is, of course, a hypothetical scenario and 
not inevitably a consequence of the UK leaving the EU (see Chapter 6, 
Scenarios).
171. The researcher mobility afforded by the EU’s fundamental principle 
of freedom of movement is of critical importance to the UK science 
community, including academia, businesses and charities. It is vital 
that the flow of researchers—both coming to the UK and UK nationals 
working overseas—is not restricted. We conclude that researcher 
mobility must be protected if UK science and research is to remain 
world-leading.
172. Our report on international science, technology, engineering and 
mathematics (STEM) students, published in 2014, highlighted 
concerns about the negative impact of Government immigration 
policy on international recruitment from outside the EU.127 We are 
concerned that this situation appears to have changed little since the 
publication of our report and we recommend that the Government 
reviews its policy in this area.
Shared research infrastructures
173. Sharing large research infrastructures (RIs) allows greater efficiencies of 
cost, collaborative opportunities and access to a wider range of facilities than 
would be possible if hosted alone. We explored this area in detail in our 
report on scientific infrastructure.128
174. Europe hosts a number of shared RIs. Indeed, Professor Steve Cowley, Chief 
Executive Officer, UK Atomic Energy Authority, told us that: “many of 
the great scientific instruments of our time, of the 21st century, are now in 
Europe.”129
175. Professor Cowley continued:
“There is no question but that the European infrastructures have made 
us better and, by making us better, they make us collaborate with more 
people in the world.”130
176. EU membership is not a requirement to participate in most shared European 
RIs. However, the EU does play a role in the participation of Member States 
and Associated Countries. Professor John Womersley, Chief Executive 
Officer of the Science and Technology Facilities Council (STFC) and 
current Chair of the European Strategic Forum on Research Infrastructures 
(ESFRI), outlined the function and limits of the European Commission in 
facilitating collaborations to address large scale challenges:
“the way to address these big science questions requires international 
collaboration and the pooling of resources. The mechanisms to do that 
are facilitated by the European Commission, but not funded by it”131
127 Science and Technology Committee, International Science, Technology, Engineering and Mathematics 
(STEM) students (4th Report, Session 2013–14, HL Paper 162)
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177. Wide access to many RIs is available to non-EU Member States as well as to 
countries outside Europe. We have found there to be confusion within the 
science community with regards to which infrastructures are EU-managed 
and which are European in nature. In terms of the latter, the UK is involved 
directly rather than as a Member State of the EU.
178. Although not a pre-requisite for involvement, EU membership can facilitate 
influence and provide platforms to collaborate. The European Commission 
outlined their role in European shared RIs:
“The scope of the research infrastructures part of the programme is 
to facilitate the development of world-class research infrastructures in 
Europe, to integrate and open national research infrastructures, to foster 
the innovation potential of the infrastructures and their human resources, 
and to reinforce European policy and international cooperation through 
synergies by setting up partnerships between relevant policy makers, 
funding bodies or advisory groups.”132
179. Pan-European RIs are funded by participating countries. The EU can aid 
planning and coordination of these through the European Strategic Forum 
on Research Infrastructures (ESFRI). ESFRI aims to support a coherent, 
strategy-led approach to policy-making on research infrastructures in 
Europe, and to facilitate multilateral initiatives leading to the better use and 
development of research infrastructures. Professor John Womersley is the 
current Chair of ESFRI. He told us of the nature and function of the group:
“ESFRI is hosted by the European Commission: That means it 
provides meeting rooms and a secretariat, but it has no budget from 
the EC; in fact, it has no budget from anywhere. It is a set of delegates 
from national governments who come together to construct a mutually 
agreed roadmap of next-generation scientific facilities that they will 
then voluntarily decide to join or not, on the basis of individual national 
contributions.”133
180. The UK hosts the headquarters of five pan-European RIs. These are:
• ELIXIR (European Life-science Infrastructure for Biological 
Information) in Hinxton, Cambridgeshire;
• Integrated Structural Biology Infrastructure (INSTRUCT) in Oxford;
• Infrastructure for Systems Biology-Europe (ISBE) in London (Imperial 
College);
• Square Kilometre Array (SKA) in Manchester (Jodrell Bank); and
• European Social Survey (ESS ERIC) in London (City University).
181. In addition, the UK houses ten facilities that are part of pan-European RIs 
headquartered in other European countries and is also a member of pan-
European RIs entirely based outside the UK, such as the European Hard 
X-Ray Free Electron Laser (European XFEL) based in Germany.
132 Written evidence from European Commission (EUM0081)
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182. As well as being involved with pan-European RIs, the UK is also a part of 
intergovernmental research organisations, including CERN and the ITER 
fusion experiment. Each of these organisations has its own institutional 
arrangements and membership rules. The EU plays a different role in each; 
some were founded before the formation of the EU. It is difficult to quantify 
the role of the EU in forming and/or maintaining these bilateral and multi-
lateral intergovernmental collaborations and, for those founded after the EU 
was created, to assess whether they would have developed in its absence.
183. Professor John Womersley told us that the UK had been hesitant in hosting 
shared RIs in the past. However, he indicated that this attitude had now 
changed:
“I think that [attitude] has shifted because we have rediscovered the 
knowledge that there are long-term benefits to having such things on 
our soil. Those come from the economic impacts, the spin-outs; from 
the fact that these facilities serve as an ecosystem for small businesses, 
or even for large companies to locate around them, and that they have a 
pool of staff who can go on to stimulate economic activity.”134
184. The next section will look at three pan-European RIs and two 
intergovernmental research organisations in more detail: the European 
Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-
EBI) and ELIXIR; the European Social Survey (ESS); the European 
Organisation of Nuclear Research (CERN); and the ITER nuclear fusion 
experiment. These will serve to highlight the difference between European 
science and EU science and are chosen to reflect the variety and nature of 
different types of European and/or EU collaborative infrastructure projects.
European Molecular Biology Laboratory European Bioinformatics Institute 
(EMBL-EBI) and ELIXIR135
185. The European Molecular Biology Laboratory (EMBL) conducts basic 
research in molecular biology, engages in technology development and 
provides infrastructure, facilities, training and services for researchers.
186. An intergovernmental treaty organisation established in 1974, EMBL has 
21 countries as full members. All of these countries are European; there 
are two non-European associate Member States (Australia and Argentina). 
Countries with full membership include both EU Member States and non-
Member States; EU membership plays no part in allowing membership of 
EMBL.
187. EMBL’s headquarters and main laboratory are located in Heidelberg, 
Germany. All four countries that house EMBL outstations are Member 
States. The outstations are:
• EMBL-EBI (The European Bioinformatics Institute) Hinxton, UK;
• EMBL Grenoble, France;
134 Q 111 (Prof John Womersley)
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• EMBL Hamburg, Germany; and
• EMBL Monterotondo, Italy.
188. EMBL member countries make a contribution to EMBL’s programmes, 
receive access to all services and programmes and are responsible for all 
important decisions about the organisation and its activities taken in the 
EMBL Council. Associate Member States have a reduced membership 
contribution to the budget of the laboratory and participate in EMBL 
Council meetings as observers.
189. EMBL exists and acts independently from the EU, but synergises activities 
with the European Commission. Cooperation is based on a Memorandum of 
Understanding implemented through biannual work plans. This agreement 
grants the European Commission ‘observer status’ in EMBL.
190. The UK was the third highest individual contributor to EMBL in 2014, after 
Germany and France. EMBL does not receive direct funding from the EU; 
however, EU funding programmes for research remain the biggest external 
funding source for EMBL. In 2014, 30% of the external funding awarded to 
EMBL originated from the EU.
191. The branch of EMBL located in the UK, EMBL-EBI, hosts the European 
Life-science Infrastructure for Biological Information (ELIXIR). ELIXIR 
is a pan-European research infrastructure (RI) for biological data. It is 
an initiative to coordinate, sustain and integrate Europe’s life science 
bioinformatics resources. Sixteen countries (as well as EMBL) are members 
of ELIXIR; these are all European and include Member States and non-
Member States such as Switzerland, Norway and Israel. An additional two 
countries have observer status. ELIXIR has been recognized by ESFRI as a 
priority Research Infrastructure for Europe, and has since been awarded a 
major Horizon 2020 grant in recognition of this.
192. Though EU membership does not influence the UK’s ability to be a member 
of EMBL or ELIXIR, it was suggested to us that EU membership does play 
a role in the location of EMBL laboratories and the decision to headquarter 
ELIXIR in the UK. The submission received from EMBL-EBI stated:
“EMBL-EBI would not have been able to participate so fully, or even 
at all, in these infrastructure projects were the UK not an EU member, 
and EMBL-EBI’s selection as the hub for ELIXIR would certainly have 
been in question were the UK not part of the EU.”136
193. Professor Dame Janet Thornton, former Director of EMBL-EBI and 
coordinator of the preparatory phase of ELIXIR, said of the establishment 
of ELIXIR:
“I do not think that would have happened if we were not part of the 
EU.”137
136 Written evidence from the European Bioinformatics Institute (EUM0038)
137 Q 6 (Prof Dame Janet Thornton)
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European Social Survey (ESS)138
194. The European Social Survey (ESS) is a pan-European research infrastructure 
whose headquarters are located within City University in London.
195. The ESS was one of the first RIs to be awarded European Research 
Infrastructure Consortium (ERIC) status. ERIC status was developed by 
the European Commission to provide a supranational legal framework to 
facilitate the creation of shared research infrastructures between EU countries 
in response to concerns that national laws did not fulfil the needs of new 
European infrastructures.139 Only Member States, Associated Countries, 
Third Countries (other than Associated Countries) and intergovernmental 
organisations can be members of an ERIC. Twelve research infrastructures, 
including ESS, currently have ERIC status.140 We heard from Professor Kurt 
Deketelaere about the value of the development of ERIC status:
“the ERIC regulation that the European Union has adopted, which 
makes it possible to negotiate to organise in a legal way consortia for the 
building up of research infrastructure, this has been a very beneficial 
initiative.”141
196. The ESS ERIC is a cross-national survey that has been conducted every two 
years in Europe since 2001. It measures the attitudes, beliefs and behaviour 
patterns of diverse populations in more than 30 nations.
197. There are 15 member countries of the ESS ERIC, 14 of which are EU 
Member States. Norway has recently joined but is not an EU Member State. 
The single observer country is Switzerland. All participating countries are 
required to contribute to the central coordination costs of the ESS ERIC; 
this contribution is made up of a basic membership fee and an additional 
amount, calculated according to the GDP of each country.
198. Professor Paul Boyle, President and Vice-Chancellor, University of Leicester, 
told us of the value of the UK’s participation in the ESS ERIC:
“One country could not establish it financially, but there is also the 
question of getting the buy in from the various organisations that need 
to be involved. Similarly, if you are not one of the players, you do not 
shape and influence the survey questions to anywhere near the same 
degree as the countries that are contributing through the European 
collaboration. Although we allow other countries to be involved, 
inevitably the influence on how that survey shapes up is challenging if 
you are not one of the funders through the European Community.”142
138 European Society Survey: http://www.europeansocialsurvey.org/ [accessed 12 April 2016] Much of 
the information that follows is drawn from this source.
139 On 2 December 2013, the Council adopted the Council Regulation EU n° 1261/2013 amending the 
Regulation EC 723–2009 concerning the ERIC. The participation of countries associated to the 
EU Research Framework Programmes in ERICs is now on the same footing as EU Member States. 
Their contributions to ERICs will be fully reflected in terms of membership and voting rights. The 
regulation entered into force on 26 December 2013.
140 European Commission, Research and Innovation, Infrastructures, European Research Infrastructure 
Consortium (ERIC) (February 2016): https://ec.europa.eu/research/infrastructures/index_en.cfm 
?pg=eric#eric [accessed 12 April 2016]
141 Q 8 (Prof Kurt Deketelaere)
142 Q 13 (Prof Paul Boyle)
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European Organisation of Nuclear Research (CERN)143
199. The European Organisation of Nuclear Research (CERN) is an 
intergovernmental research organisation, the facilities of which are situated 
near Geneva in Switzerland. The largest particle physics laboratory in the 
world, CERN houses particle accelerators and detectors, such as the Large 
Hadron Collider. CERN organises and sponsors international research 
collaborations, promoting contacts between scientists and interchange with 
other laboratories and institutes. The experiments conducted at CERN are 
the result of large-scale international collaborations.
200. The UK is involved directly in CERN as one of 21 member nations. 
Members include 18 EU Member States as well as Switzerland, Norway and 
Israel. Professor John Womersley emphasised to us that the facilities hosted 
by CERN are a European rather than an EU research infrastructure:
“when you talk about things such as CERN as a European success, 
indeed it is, but it is a voluntary collaboration of European governments 
and, in fact, it predates the establishment of the European Union.”144
201. A number of nations from outside Europe have non-member status at CERN, 
meaning they do not participate in organisational decision making but have 
co-operation agreements to participate in specific projects.
202. The EU is not directly involved in the organisation of CERN activities 
nor its policies but has ‘Observer Status’. In 2014, the EU provided 1.6% 
of CERN’s funding. While this direct investment from the EU at CERN 
is relatively low, EU-funded research projects conduct work at CERN and 
collaborate with researchers who conduct work at CERN. Research Councils 
UK (RCUK) said of the interactions between CERN and the EU:
“CERN then engages in a broad portfolio of EU-funded programmes for 
research and e-infrastructures, for example through providing key inputs 
into coordinating the EU-funded computing grid initiative alongside 
its USA and other regional counterparts, to build a global computing 
infrastructure. EU funding has contributed to the development of the 
high luminosity upgrades for the Large Hadron Collider (LHC) and the 
development of advanced detector technologies.”145
The ITER nuclear fusion experiment146
203. ITER is a multinational project and involves the EU, China, India, Japan, 
South Korea, Russia and the USA. It is an intergovernmental research 
organisation and the UK’s contribution is managed by the EU; the UK is 
not involved directly. As Professor John Womersley said to us:
143 Royal Society, UK research and the European Union: The role of the EU in funding UK research (December 2015): 
https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf [accessed 
 12 April 2016] and CERN: http://home.cern/ [accessed 12 April 2016] Much of the information that 
follows is drawn from these sources.
144 Q 108 (Prof John Womersley)
145 Written evidence from Research Councils UK (EUM0016)
146 Royal Society, UK research and the European Union: The role of the EU in funding UK research (December 2015): 
https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf [accessed 
 12 April 2016] and ITER: https://www.iter.org/ [accessed 12 April 2016] Much of the information 
that follows is drawn from these sources.
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“ITER/JET at Culham is one of the few areas where there really is an 
EU flag on the outside of a big research project.”147
204. ITER is intended to demonstrate the scientific and technological feasibility 
of nuclear fusion as an energy source and to pave the way for a functioning 
fusion power plant. When construction is complete, it will be the world’s 
largest experimental tokamak nuclear fusion reactor. It is located in the 
south of France.
205. The EU’s commitments to the ITER Agreement were agreed through the 
European Atomic Energy Community (EURATOM) Treaty.148 The EU is 
contributing 45% of the construction phase (buildings, machine components 
and assembly) cost and 34% of the cost of operation, deactivation and 
decommissioning of the facility. The other six parties are contributing 
approximately 9% each. The current cost estimates for the EU contribution 
to the ITER construction phase (2007–20) amount to €6.6 billion. UK 
industry has so far been awarded over €300 million worth of contracts as 
part of the ITER project (ranked third behind France and Italy).
206. The UK Atomic Energy Authority (UKAEA) is involved in the UK’s 
interactions with ITER via the EU. On the UK’s membership of the EU and 
the effect this has on collaboration, the submission from the UKAEA stated:
“Full involvement means that the UK has excellent unhindered access 
to facilities, leading science teams and the R&D developed, including 
JET and ITER. Indeed, EU funding and collaboration is essential to 
sustain the world leading capability of Culham and to position the UK 
in the technologies of the future fusion (and fission) economy.”149
207. The UK gains significant value from being involved in a number of 
pan-European Research Infrastructures (RIs), both as a host country 
and as a user of facilities hosted outside of the UK. We conclude 
that such European based, but non-EU, RIs, although formally 
independent of the EU, are in fact interlinked to varying degrees.
147 Q 111 (Prof John Womersley)
148 Initially created to coordinate the Member States’ research programmes for the peaceful use of 
nuclear energy, the Euratom Treaty today helps to pool knowledge, infrastructure and funding of 
nuclear energy. It ensures the security of atomic energy supply within the framework of a centralised 
monitoring system. EUR-Lex Access to European Union Law, Treaty establishing the European 
Atomic Energy Community (Euratom) (October 2010): http://eur-lex.europa.eu/legal-content/EN/
TXT/?uri=URISERV%3Axy0024 [accessed 12 April 2016]
149 Written evidence from the United Kingdom Atomic Energy Authority (EUM0024)
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CHAPTER 6: SCENARIOS
208. Our inquiry was principally concerned with exploring the ways in which EU 
membership affects UK science and research. Inevitably, however, discussions 
veered towards consideration of the implications of Brexit. As such, a range 
of hypothetical arrangements and situations were contemplated. We do not 
wish to dwell unduly on the almost limitless number of post-Brexit scenarios, 
but there is value in highlighting the main arguments and hypotheses that 
were rehearsed. Furthermore, we offer some areas which merit attention in 
the event of the UK choosing to remain in the EU.
Repatriation of EU funds
209. It was suggested that, in the event of Brexit, the UK Government could re-
invest an amount equivalent to current EU funds for science into the national 
science budget. There was, however, no absolute consensus regarding the 
likelihood of this scenario. Professor Dame Helen Wallace, representing the 
British Academy, speculated that:
“The Treasury—George Osborne at least is very keen on science, as we 
know—might allow for some enhanced science spending, but it would 
not necessarily have the same criteria of mobility and international 
collaboration that characterise European funds. My guess is that it 
would be not as much, it would not be ring-fenced and it would have 
different characteristics.”150
210. Professor Angus Dalgleish, spokesperson for Scientists for Britain, thought 
it likely that the Government would re-invest equivalent funding into the 
science budget:
“I think that it would be for a scientist to lobby so that money came back 
from the Government, because the Government would have more than 
enough to be able to do it without having to lose elsewhere. I think that 
would have to make it very likely.”151
211. Mr Emran Mian, Director, Social Market Foundation argued, however, that 
it was hard to imagine science and research funding being an immediate 
priority:
“In principle, there is no reason why the gap would not be made up. It 
is a very hopeful position, not least because in the event of Brexit there 
would be quite significant economic pressure not only on sterling—and 
the depreciation of sterling has direct impacts on how research moneys 
are spent or allocated—but, equally, there would be other economic risks 
to the UK. It might be that over time those risks would be smoothed 
out, so if you looked at it over 20 or 30 years the UK might be fine, but 
the immediate impact would be negative. It is very difficult to see in that 
negative scenario why science and research would be a priority for the 
UK.”152
212. The University of Manchester asserted that there were three arguments 
which countered the view that if the UK were to leave the EU funds would 
150 Q 47 (Prof Dame Helen Wallace)
151 Q 131 (Prof Angus Dalgleish)
152 Q 131 (Emran Mian)
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be invested nationally. Moreover, they queried the desirability of forfeiting 
the EU funding stream:
• There is “no guarantee” that repatriated funds would be designated for 
research;
• Research flourishes when there is plurality of funding sources; and
• In some circumstances more value can be achieved from a research 
investment made at EU level, as there is “ample evidence of inefficiencies 
and delays caused by the need of national agencies operating under 
different rules, priorities and timescales seeking to co-fund a shared 
project.”153
213. Furthermore, the Minister of State for Universities and Science, Jo Johnson 
MP, himself expressed uncertainty regarding the likelihood of repatriating 
funds:
“it would be rash to pretend that it would be easy to replace it [the 
financial contribution from the EU to UK science and research] in the 
event of Brexit when we would not know what other claims there might 
be on the public purse, nor what state our economy would be in.”154
Contingency planning in the event of Brexit
214. Given the consensus regarding the importance of EU funding for UK science 
and research, we sought to determine whether a process of contingency 
planning in the event of Brexit had been initiated within the Department for 
Business, Innovation and Skills.
215. After repeated questioning, the Minister of State for Universities and Science, 
Jo Johnson MP, was not able to confirm that contingency plans were being 
prepared for science in the UK. Instead, he said:
“This is a question for the whole of Government with respect to the 
EU referendum and possible outcomes of it. The Government are 
campaigning for a positive vision for Britain within a reformed European 
Union, and all efforts are focusing on making sure that we have a positive 
campaign in which the facts are out there and people are able to make 
an informed choice.”155
A new regulatory framework for the UK
216. Attention also turned to whether the UK would be able to develop a more 
suitable regulatory environment in the event of Brexit. Such a scenario is 
plausible, as the Russell Group stated:
“There are a number of EU regulatory frameworks that adversely affect 
the science and research community. It is possible that if the UK were to 
leave the EU the UK may have more flexibility to set its own regulations 
which may be beneficial for science and research.”156
217. Vote Leave suggested that:
153 Written evidence from the University of Manchester (EUM0044)
154 Q 157 (Jo Johnson MP)
155 Q 148 (Jo Johnson MP)
156 Written evidence from the Russell Group (EUM0069)
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“Outside the EU, the UK would have the power to reconsider these 
Directives and Regulations. As EU law would no longer be supreme, 
the UK Parliament would be able to revise them to reduce the burden.”157
218. Syngenta indicated that there could be value in the UK developing its own 
regulatory regimes:
“Leaving the EU could mean that the UK would be free to introduce 
more scientific, risk and evidence-based approaches to the regulation 
of agricultural technologies, and therefore could be better placed to 
provide UK farmers with the latest advances.”158
219. The Royal Society of Chemistry, however, wrote of the difficulties that might 
flow from having differing regulatory regimes:
“In relation to regulation, a point made by industry respondents was the 
potential for divergent regulatory frameworks if the UK left the EU. The 
ability for the UK to set its own regulation was not viewed positively due 
to the perception that businesses would still need to comply with EU 
regulation, as well as any newly-developed UK regulation.”159
220. Similarly, the Wellcome Trust argued that:
“If the UK left the EU, while it could develop its own regulatory 
framework, which might have a national advantage, it would still be 
bound by some EU regulation, for example for large scale clinical trials. 
This would also be without the same opportunities the UK currently 
has to shape the content of legislation.”160
Mobility
221. Scientists for Britain suggested to us that freedom of movement would not 
necessarily be restricted upon Brexit. They told us that: “EU membership 
has no bearing whatsoever on this topic.”161 They continued:
“Ending EU membership does not on its own predicate a change in 
freedom of movement. There are several non-EU European states that 
maintain free movement with the EU. Freedom of movement would 
have to be assessed separately by the UK electorate if voters had chosen 
to leave the EU.”162
222. Emran Mian, Director, Social Market Foundation, suggested to us, however, 
that: “It is very difficult for me to see a scenario of Brexit in which researcher 
mobility is not in some way impaired.”163 He argued that mobility was 
important because researchers coming to the UK from other EU countries :
“bring a set of networks already with them and we then take advantage 
of those networks in making our universities and research projects more 
competitive in funding.”164
157 Written evidence from Vote Leave (EUM0056)
158 Written evidence from Syngenta (EUM0013)
159 Written evidence from the Royal Society of Chemistry (EUM0051)
160 Written evidence form the Wellcome Trust (EUM0034)
161 Written evidence from Scientists for Britain (EUM0075)
162 Written evidence from Scientists for Britain (EUM0075)
163 Q 129 (Emran Mian)
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223. Furthermore, he questioned those arguing that the UK’s strong networks 
across the EU would be maintained as:
“some of these relationships change very quickly, and, of course, the 
frontier of knowledge changes very quickly, and the researchers who will 
be important in 10 years’ time are not the researchers who might currently 
be in the UK or currently have associations with UK universities.”165
224. He concluded:
“The real question is how we would maintain mobility and the making 
of connections. That feels to me very much like a leap in the dark in the 
event of exit. For me, the biggest area of hesitation is what would happen 
to researcher mobility and what impacts that would have.”166
Associated Country Status
225. The implications of the UK leaving the EU and becoming an Associated 
Country were raised on numerous occasions. As previously outlined in 
Chapters 4 and 5, non-Member States can participate in EU funding schemes 
and collaborative platforms. There is therefore an argument that the UK 
could reap the rewards of EU membership in the event of Brexit by gaining 
Associated Country status. It was put to us, however, that were the UK to 
leave the EU, then the UK may face consequences which would mitigate 
against a smooth and fruitful change in the nature of the relationship. 
Professor Dame Janet Thornton speculated that “if we left the EU we have 
no doubt that there will be retribution.”167
226. There are currently 13 Associated Countries including Norway, Iceland, 
Israel and Switzerland.168 These countries are not members of the EU 
but participate in EU Framework Programme funding schemes. Bilateral 
agreements are in place with each Associate and terms of association vary 
from one country to another. Associated Countries generally contribute to 
EU budgets based on GDP and researchers can apply for funding as those 
in Member States do. Thus, in the case of funding awarded on the basis of 
research excellence, Associated Countries are able to be net gainers in terms 
of funding.
227. Scientists for Britain cited the examples of Norway, Switzerland, Turkey, 
Iceland and Israel as non-EU countries that participate in and contribute to 
the science programmes operated via the EU, arguing that if the UK were to 
leave the EU, it would be perfectly possible to continue to participate in EU 
science networks in a similar vein.169
228. While there was broad agreement that Associated Country status could 
afford the UK access to EU funding schemes, concerns were raised about 
the level of influence that the UK would be able to have in decision-making 
processes and within advisory panels. The UK currently has significant 
influence on the development of EU policy for science. It is not entirely clear 
how this would be affected in the event of termination of membership and 
adoption of Associated Country status.
165 Q 135 (Emran Mian)
166 Q 135 (Emran Mian)
167 Q 6 (Prof Dame Janet Thornton)
168 See Appendix 6 for a full list of Associated Countries.
169 Written evidence from Scientists for Britain (EUM0075)
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229. We were presented with forthright views that the UK, in the event of 
becoming an Associated Country, would lose its seat at the table when 
decisions were being made. Professor Dame Helen Wallace, representing the 
British Academy, claimed that:
“What the British would lose in that scenario is the opportunity to be full 
participants in shaping the direction of travel of programmes, because 
you would be takers, not makers, of the policy process and guidelines.”170
230. Sir Emyr Jones Parry, GCMG, President, the Learned Society of Wales, 
argued:
“The point is that we would be impoverished, diminished, by taking 
that course of action [leaving the EU]. That is not an argument against 
universities being international; of course they are international much 
beyond the European Union, but the EU dimension in what it has 
brought—the competitiveness, the incentive, the resources—has actually 
benefited very considerably the sector.”171
231. Professor Kurt Deketelaere, Secretary-General, League of European 
Research Universities (LERU), stressed the importance of having a voice in 
discussions:
“It is important to be around the table, to be able to say what the 
problems are and what the solutions should be. Simplification, excellence 
and investment in research and innovation are going to become much 
more difficult if you are no longer around the table and no longer have 
a voice.”172
232. Professor Sir Leszek Borysiewicz, Chair of the Russell Group’s EU Advisory 
Group, and Vice-Chancellor, University of Cambridge, expressed concerns 
relating to intellectual property:
“Associated member status carries with it a huge disadvantage, 
particularly if we think of the outcomes of that research as they 
will pertain to the capacity of the UK to exploit them. If you are an 
associated country you have to negotiate that position on intellectual 
property in a separate way because you do not form part and parcel 
of those areas. Were we outside the European Union, it is quite likely 
that we might still be invited because of the quality of research that is 
undertaken in Europe, but there is no way that any discoveries would 
then be exploited necessarily in the UK because we would not hold the 
intellectual property; it would be held by member states. I believe that 
being there is a huge advantage.”173
233. It would seem likely that scientists from Associated Countries participating 
in EU programmes are able to have some influence, at least at an operational 
level. The point was repeatedly made to us, however, that they would wield 
no influence when the high level, strategic decisions were made. Professor 
Robin Grimes, Chief Scientific Adviser, FCO, argued:
170 Q 51 (Prof Dame Helen Wallace)
171 Q 51 (Sir Emyr Jones Parry)
172 Q 2 (Prof Kurt Deketelaere)
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“There are some non-EU countries that are part of the European 
research area and they sit on the European research area committee, but 
they do not get a seat at the table when the Council of Ministers or the 
Parliament are setting the rules or deciding on budgets and planning 
programmes.”174
234. Similarly, Dr Mike Galsworthy, Scientists for EU, argued:
“If we were to pull out, then we would no longer have our Government 
representing us in the Council nor our 73 MEPs. In deciding, two 
things are important. One is the legislation around science, which is 
rapidly changing, and the second is actually the nature and the priorities 
of the science programme itself. In both of those, there are priorities set 
initially at the Commission level, listening to all the interests of those 
around them, which will be prioritised for their members over any 
external parties. That filters down through the Parliament, which would 
have to agree to it, in which we would have no representation.”175
235. The UK might wish to become an Associated Country in the event 
of Brexit. We heard, however, strong views that the UK would lose 
its influence and roles in setting strategic priorities and in decision-
making. If Associated Country status were to be pursued, further 
investigation would be required in order to ascertain to what extent, 
and at what expense, the UK’s currently influential position would be 
diminished.
Switzerland
236. Much of our consideration of Associated Country status was viewed through 
the lens of the example of Switzerland, and we think it is instructive to 
consider the Swiss example in a little more detail. As a world-renowned, 
high-performing scientific nation and non-member of the EU, Switzerland 
was repeatedly highlighted as an example that the UK could follow in the 
event of Brexit.
237. Switzerland is not a Member State, nor a member of the European Economic 
Area (EEA); it is, however, an Associated Country and a participant in the 
single market. Switzerland participates in the EU’s fundamental principle 
of freedom of movement via a bilateral agreement.176 Thus, Swiss nationals 
are afforded the same mobility as those from Member States (and member 
countries of the EEA) are.
238. While we heard a number of arguments for why EU membership is vital 
for various aspects of science, the example of Switzerland—a research 
community thriving in spite of lack of EU membership—gave us pause for 
thought.
239. Professor Phillipe Moreillon, Vice Rector, Research and International 
Relations, University of Lausanne, Switzerland, provided us with a number 
174 Q 127 (Prof Robin Grimes)
175 Q 130 (Dr Mike Galsworthy)
176 Agreement between the European Community and its Member States, of the one part, and the Swiss 
Confederation, of the other, on the free movement of persons, OJ L 114 , 30/04/2002 P. 0006–0072: 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:22002A0430(01):EN:HTML 
[accessed 12 April 2016]
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of insights regarding Swiss science. He told us of the high performance of 
the Swiss science community and how European interactions influence this:
“Our raw material is science and, talking egoistically from the point of 
view of small Switzerland, with the networking and the fact we have 
attracted many scientists from all over the world to work, we have 
a scientific jewel, if you will. Now, we are out of the big networking 
from Europe, so you may say we can have networking with the United 
States, India, China et cetera, but our direct scientific neighbours are 
the European countries, and they have built this European area of 
knowledge, education and research, and we would be foolish not to use 
it.”177
240. He also stressed the importance of the permeability of Swiss borders:
“Fifty per cent of Swiss researchers have non-Swiss passports. This is 
important. I guess it is not very different from the UK. Thirty per cent of 
Swiss researchers come from Europe, from neighbouring countries, so 
the networking and mobility that was alluded to in the previous session 
is quite important, at least for Switzerland.”178
241. Addressing the question of the influence that Associated Countries have, 
Professor Moreillon told us: “If you work with European colleagues, or if you 
are applying for ERC funding, or if you are funded by Europe, you abide by 
the European rules.”179 He also alluded to Switzerland having a position of 
lesser influence than full Member States:
“When we became an associate, it was much, much easier, of course, 
but we are still not sitting at the decision table or on the consultative 
committees where the decisions are made. We have a number of ways 
to interact, such as through university associations. We are still in the 
corridor, but at least we are part of the whole programme.”180
242. In a number of areas, Switzerland has its own national regulatory frameworks. 
The regulatory environment for clinical trials is a prominent example of this.181 
Professor Siegfried Russwurm, Chief Technology Officer & Member of the 
Managing Board of Siemens AG, referred to these national frameworks as 
“peculiar rules and regulations.”182 He provided us with the viewpoint from 
a multinational business in terms of operating within such frameworks:
“We have to make up our minds whether special Swiss regulations are 
worth the buck to implement them for such a small market. Siemens 
does not want to wipe out this Swiss industrial tradition, so we keep 
this traditional headquarter up and running, with all the emotions that 
surround that, but frankly we have been reducing our R&D in this 
location constantly over the last 15 years.”183
177 Q 141 (Prof Philippe Moreillon)
178 Q 137 (Prof Philippe Moreillon)
179 Q 140 (Prof Philippe Moreillon)
180 Q 138 (Prof Philippe Moreillon)
181 Switzerland operates its own clinical research rules (Swiss Human Research Act) that are different to 
the EU’s Clinical Trials Regulation.
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243. While this is an interesting perspective from Professor Russwurm, it must 
be noted that a number of research-intensive multinational businesses are 
headquartered in Switzerland.
244. During our exploration of Switzerland’s affiliation with the EU, the 
sanctions imposed by the latter in response to the Swiss national referendum 
in February 2014 that narrowly voted to curtail freedom of movement were 
repeatedly highlighted to us. These sanctions had an effect on the science 
community. Switzerland was suspended from access to Horizon 2020. 
As such, the Swiss government was forced to replicate at national level a 
temporary programme to replace immediate access to the ERC programme 
and subsequently negotiated limited access to H2020, with much reduced 
admittance to programmes, exclusion from the new SME Instrument and 
loss of ability to coordinate collaborative research within H2020. The Swiss 
were also not included in Erasmus Plus.
245. We heard from a number of witnesses that these sanctions should be viewed as 
a warning to the UK on the implications of invoking restrictions on freedom 
of movement. Dr Mike Galsworthy, Programme Director of Scientists for 
EU, suggested that the EU’s sanctions on Switzerland should be viewed as 
the establishment of a precedent:
“Given that, on Brexit, we would most likely adopt a model that goes 
back on, or cancels, our freedom of movement arrangements with the 
EU, the real risk is that Switzerland is a strong precedent for the model 
that would be used for us.”184
The UK remains in the EU
246. In the event that the UK chooses to remain part of the EU, this should 
not preclude the UK Government from advancing reforms to enhance 
the interactions between the EU and UK science and research. While 
the overwhelming view we received was very positive about the impact of 
EU membership on science and research in the UK, even those who were 
arguably most in favour of continued EU membership—the university 
sector—pointed out that not all interactions were beneficial and were 
critical of aspects of the EU. Professor Sir Leszek Borysiewicz, Chair of the 
Russell Group’s EU Advisory Group, and Vice-Chancellor, University of 
Cambridge, told us:
“I would hate the Committee to take away the idea we have such a rosy-
eyed view of the European Union that it can do no wrong; we certainly 
do not. There are good examples of where considerable difficulties have 
been posed by directives and issues within the EU. I just pick on one, 
and that is the directive about intellectual property related to embryonic 
stem cell development. That is forcing an institution like Cambridge to 
look for exploitation in California or India in relation to these areas. It 
is not that everything that comes out of Europe glows and is brilliant—
there are the issues with clinical trial directives and the welfare of animals 
in relation to experimental work—but the important thing is that we do 
have allies within Europe and we can engage in that discussion and 
debate.”185
184 Q 130 (Dr Mike Galsworthy)
185 Q 67 (Prof Sir Leszek Borysiewicz)
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247. The Russell Group, in its written submission, elaborated further on the 
potential for reforms within the EU which could improve science and research 
in the UK. They highlighted the potential to develop better regulatory 
frameworks:
“The EU is not perfect by any means and we would support EU reforms 
particularly those which enhance our universities’ ability to benefit 
further from forging productive collaborations across Europe. One of 
the Prime Minister’s key areas of reform is to boost the competitiveness 
and productivity of the EU; research and innovation should be at the 
heart of this, as key drivers of growth and jobs. There is also a focus on 
cutting red tape, which would be welcome, particularly if the regulatory 
burden on UK universities could be reduced.”186
248. As discussed in Chapter 4, when the figures for the participation of UK large 
businesses in Framework Programme 7 are considered it is clear that there 
is scope for this area of the UK’s engagement with the EU to be improved. 
Large businesses in the UK under-perform when compared to key competitor 
nations and performance is below the EU average. When comparing this 
participation to that in Germany, Professor Siegfried Russwurm, Chief 
Technology Officer & Member of the Managing Board of Siemens AG, saw 
fit to proffer some advice:
“The only humble advice that I could offer would be to synchronise 
national science funding with these programmes. Frankly, if it is our 
tax money that is spent via these programmes, then let us come to the 
conclusion that our national programmes should help companies and 
universities to make their way into these European programmes. Over 
the course of recent years, we have managed national programmes to 
help companies and universities to get their act together and be more 
successful in European programmes. We do not put that into the 
headlines, but it is a matter of fact, and I am not shy about testifying 
that to this Committee.”187
249. As well as exploring synergies between national programmes that support 
businesses with those provided by the EU, we consider that it would be 
appropriate for the Government to review its support for businesses in 
engaging with EU funding schemes in light of the abolition of the Regional 
Development Agencies (RDAs), as discussed in paragraphs 130–135 in 
Chapter 4 in the section on business and innovation.
250. Even those who were most in favour of continued membership of the 
EU—the university sector—criticised aspects of the UK’s relationship 
with the EU. We therefore conclude that, in the event that the UK 
chooses to remain part of the EU, there would be scope for the UK 
Government to advance reforms to enhance the interactions between 
the EU and UK science and research. We suggest that a particular 
areas of focus should be the influence of the EU on the UK’s regulatory 
environment and the support available for UK businesses in order to 
facilitate engagement with EU funding schemes.
186 Written evidence from the Russell Group (EUM0069)
187 Q 104 (Prof Siegfried Russwurm)
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APPENDIX 3: CALL FOR EVIDENCE
The House of Lords Science and Technology Select Committee, under the 
Chairmanship of Lord Selborne, is conducting an inquiry into the relationship 
between EU membership and the effectiveness of science, research and innovation in the 
UK. The Committee invites interested individuals and organisations to submit 
evidence to this inquiry. The deadline for written evidence submissions is Friday, 
20 November 2015.
Background
The UK’s membership of the EU has wide ranging influence on the vitality of 
UK science, research and innovation. Understanding this influence, however, 
is complex and multifaceted. Its exact nature is uncatalogued in a number 
of key areas and this inquiry aims to try and understand and characterise the 
interactions between EU membership and the effectiveness of science, research 
and innovation in the UK. Funding for research and innovation, collaboration, 
regulatory frameworks and scientific advice are four areas that we have identified 
as of paramount importance, though we would welcome information under 
additional headings if appropriate.
The EU-level funding mechanisms available to UK researchers are myriad 
and a number are highly intricate. These include European Research Council 
funding, Horizon 2020 programmes (formerly Framework Programme 7), Joint 
Programming Initiatives (JPI) and European Innovation Partnerships. As well 
as public funding, private investment in UK research and development from 
international (both EU and non-EU) and UK-domiciled businesses is also 
increasingly recognised as crucial to the performance of the science base as a 
means to maintain competitiveness and productivity. The UK’s EU membership 
may serve to make the UK a more or less attractive location for investment. As 
such, membership may influence access to public, private and charitable funding.
Science is, by its very nature, a collaborative endeavour and key breakthroughs are 
often the result of collaborations between researchers across the globe. In addition 
to funding, researchers from across the UK have access to shared infrastructure 
as part of EU partnerships and other international relationships. Shared 
infrastructure allows for sharing of costs, expertise and facilitates larger scale 
investments. Within the EU, freedom of movement allows researchers to work in 
universities, research institutes and industry with relative ease. For example, EU 
Marie Sklodowska-Curie fellowships fund scientists from any EU country to work 
in any other, and the ERASMUS programme, likewise, allows unimpeded flow of 
students and teaching staff across the EU.
Much of the science carried out in the UK is regulated by EU frameworks and 
directives. The clinical trials landscape and research into genetically modified 
organisms (GMOs) are two examples of areas dominated by regulations drawn 
at a European level. Innovation in the UK is also highly influenced by EU-level 
legislation and regulation and is affected by the balance (or imbalance) struck 
between regulation and innovation.
There are a number of mechanisms for the provision of science advice and the 
input of scientific evidence within the EU. The most high profile of these was 
arguably the position of European Chief Scientific Adviser, a post created by 
President Barroso during his term in office. Under President Juncker’s Presidency, 
however, a new Scientific Advice Mechanism (SAM) is under development as 
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a replacement. The strength of the EU science advice environment is untested 
but it will impinge on the plethora of ways in which UK science, research and 
innovation interact with the EU.
We are interested in four major themes; funding, collaboration, regulation and 
scientific advice, and the questions below seek to probe these themes. These 
questions, however, do not necessarily amount to a definitive listing of the key 
issues; respondents are therefore encouraged to draw attention to all relevant 
issues falling under the four themes, as they see fit, and not be limited by the 
questions posed.
Funding
1. What is the scale of the financial contribution from the EU to science and 
research in the UK? How does the financial contribution the UK receives 
compare with other member states in terms of, for instance, population, 
GDP, scientific strength or any other relevant indicators?
2. What is the scale of the financial contribution from the UK to the EU that 
supports science and research activities?
3. What is the effectiveness and efficiency with which these funds are managed 
in the EU compared to the management of science funding in the UK? 
Particularly, when administrative overheads, quality of decision-making and 
advisory processes are considered?
Collaboration
4. What are the benefits to UK science and research of participation in EU 
collaborations and funding programmes such as Horizon 2020 and the 
European Research Council?
5. What is the influence of EU membership on bilateral collaboration between 
the UK and other EU member states? Are collaborations with member states 
stronger than with non-EU countries as a result of EU membership? Or, 
are bilateral collaborations with member states inhibited by requirements to 
work through EU mechanisms?
6. How is private investment in UK science and research influenced by EU 
membership? Is international investment leveraged on the basis of this 
membership? How does EU membership affect the growth of research-
intensive UK companies?
7. How does the UK participate in the creation and operation of international 
facilities that are available as a consequence of our EU membership? Are 
there any restrictions in the creation and operation of international facilities 
outside the EU as a consequence of our EU membership?
8. What contribution does EU membership make to the quality of UK science 
and research through the free movement of people? How does this compare 
with flows of people between the UK and non-EU countries such as the 
USA, India, China and Singapore?
9. Does EU membership inhibit collaborations with countries outside the EU, 
for example by requiring the UK to adopt EU-wide immigration policies 
rather than bespoke ones for the UK?
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Regulation
10. What are the key EU regulatory frameworks/mechanisms that directly affect 
the science and research community in the UK?
11. If the UK were not a member of the EU, could regulations be reformed to 
give greater benefit to UK science and research? For example, in areas such 
as data regulation, VAT on shared facilities, and the use of the precautionary 
principle?
12. How is the innovation landscape affected by EU membership?
Scientific advice
13. How does the quality and effectiveness of scientific advice on matters of 
public policy compare between the EU and the UK? What are the effects, if 
any, of differences in the provision of scientific advice between the EU and 
the UK?
14. To what extent does EU membership enable UK scientists to inform and 
influence public policy at EU or international levels? To what extent does 
EU membership inhibit UK scientists from influencing public policy at EU 
or international levels?
17 September 2015
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APPENDIX 4: SEMINAR HELD AT THE HOUSE OF LORDS ON 1 
DECEMBER 2015
Members of the Committee present were Earl of Selborne (Chairman), Lord 
Cameron of Dillington, Lord Fox, Lord Hennessy of Nympsfield, Lord Hunt 
of Chesterton, Baroness Manningham-Buller, Lord Maxton, Duke of Montrose, 
Baroness Morgan of Huyton, Baroness Neville-Jones, Lord Peston, Viscount 
Ridley and Lord Vallance of Tummel.
Presentations were heard from:
• Professor Luke Georghiou, Vice-President for Research and Innovation, 
Manchester University;
• Professor Colin Riordan, President and Vice-Chancellor, Cardiff University, 
representing the International Unit within Universities UK;
• Stuart Pritchard, EU Affairs Manager, Wellcome Trust; and
• Professor James Wilsdon, Professor of Science and Democracy, Science 
Policy Research Unit (SPRU), University of Sussex.
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APPENDIX 5: ABBREVIATIONS, ACRONYMS AND TECHNICAL 
TERMS
AMRC Association of Medical Research Charities
AMS Academy of Medical Sciences
BIS Department for Business, Innovation and Skills
Brexit Refers to “British exit” from the European Union: phrase is 
commonly used to include Northern Ireland
CaSE Campaign for Science and Engineering
CCFE Culham Centre for Fusion Energy
CEH Centre for Ecology and Hydrology
CERN European Organisation of Nuclear Research
CF Cohesion Fund
COP21 21st annual conference of parties to review the implementation 
of the Rio Convention on mitigating climate change
Copernicus Formerly Global Monitoring for Environment and Security 
(GMES)
COSME Competitiveness of Enterprises and Small and Medium-sized 
Enterprises
CSA Chief Scientific Adviser
DG RTD Directorate-General for Research and Innovation
EAFRD European Agricultural Fund for Rural Development
EBI European Bioinformatics Institute
EC European Commission 
EEA European Economic Area
EEF Formerly the Engineering Employers’ Federation, now used as 
part of the name of the Manufacturers’ Organisation
EEN Enterprise Europe Network
EFSI European Fund for Strategic Investments
EIT European Institute of Innovation and Technology
ELIXIR A pan-European research infrastructure for biological data
EMBL European Molecular Biology Laboratory
EMFF European Maritime and Fisheries Fund
ERASMUS European Region Action Scheme for the Mobility of 
University Students
ERA European Research Area
ERC European Research Council
ERDF European Regional Development Fund
ERIC European Research Infrastructure Consortium
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ESFRI European Strategy Forum on Research Infrastructures
ESF European Social Fund
ESIF European Structural and Investment Funds
ESS European Social Survey
EU European Union
EURATOM European Atomic Energy Community
European 
XFEL
European Hard X-Ray Free Electron Laser
FCO Foreign and Commonwealth Office
FET Future and Emerging Technologies
FP Framework Programme
FP7 Framework Programme 7
FWCI Field-weighted citation impact
Galileo A global navigation satellite system being created by the EU 
and the European Space Agency
GCSA Government Chief Scientific Adviser
GDP Gross domestic product
GM Genetically modified
GMO Genetically modified organism
H2020 Horizon 2020
HLG High level group
IMI Innovative Medicines Initiative
INSTRUCT Integrated Structural Biology Infrastructure
ISBE Infrastructure for Systems Biology-Europe
ITER “The way” in Latin, an international experimental joint 
nuclear fusion reactor
JET Joint European Torus
JPI Joint Programming Initiative
JRC Joint Research Centre
JTI Joint Technology Initiative
KIC Knowledge and Innovation Communities
KTPs Knowledge Transfer Partnerships
LEPs Local Enterprise Partnerships
LERU League of European Research Universities
MS Member State(s)
MSCA Marie Skłodowska-Curie Actions
NIB National Institutes of Bioscience
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NNL National Nuclear Laboratory
NPL National Physical Laboratory
RCUK Research Councils UK
R&D Research and development
RDA Regional Development Agencies
REACH Registration, evaluation, authorisation & restriction of 
chemicals
RI Research infrastructure
RISE Research and Innovation Staff Exchange
RSC Royal Society of Chemistry
SAM Scientific Advice Mechanism
SKA Square Kilometre Array
SME Small-medium enterprise
STOA Science and Technology Options Assessment
STFC Science and Technology Facilities Council
TFEU Treaty on the Functioning of the EU
UKAEA UK Atomic Energy Authority
UKRO UK Research Office
UN United Nations
UUK Universities UK
VAT Value-added tax
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APPENDIX 6: MEMBER COUNTRIES OF THE EU AND 
ASSOCIATED COUNTRIES
Table 1: Member countries of the EU (year of entry)
Austria (1995) Italy (1958)
Belgium (1958) Latvia (2004)
Bulgaria (2007) Lithuania (2004)
Croatia (2013) Luxembourg (1958)
Cyprus (2004) Malta (2004)
Czech Republic (2004) Netherlands (1958)
Denmark (1973) Poland (2004)
Estonia (2004) Portugal (1986)
Finland (1995) Romania (2007)
France (1958) Slovakia (2004)
Germany (1958) Slovenia (2004)
Greece (1981) Spain (1986)
Hungary (2004) Sweden (1995)
Ireland (1973) United Kingdom (1973)
Source: europa.eu, European Union (January 2016): http://europa.eu/about-eu/countries/index_en.htm [accessed 
9 March 2016]
Table 2: Countries Associated to Horizon 2020 as of 1 December 2015
Albania Montenegro
Bosnia and Herzegovina Norway
Faroe Islands Serbia
the former Yugoslav Republic of 
Macedonia
Switzerland (partial association, see 
below)
Iceland Turkey
Israel Ukraine
Moldova
Source: European Commission Directorate-General for Research & Innovation, Associated Countries: http://
ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/3cpart/h2020-hi-list-ac_en.pdf [accessed 9 
March 2016]
Association Agreements with all of the above countries have either entered into 
force or are provisionally applicable; all Agreements apply retroactively from 1 
January 2014 (i.e. from the beginning of Horizon 2020) except for the Agreement 
with Switzerland, which is retroactively applicable as of 15 September 2014 and 
the Agreement with Ukraine which entered into force on 17 August 2015.
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APPENDIX 7: ADDITIONAL PRESENTATION OF DATA ON FP7 AND 
STRUCTURAL FUNDING FOR RESEARCH AND INNOVATION AS 
PRESENTED BY THE ROYAL SOCIETY
Difference between the percentage proportion of Framework Programme 
7 funding received and the percentage proportion of EU GDP for each 
EU Member State. 2007–13
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Source: Royal Society, UK research and the European Union The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 17 March 2016]
Difference between the percentage proportion of EU funding on for 
research, development and innovation (Framework Programme 7 and 
structural funds) received and the percentage proportion of EU GDP for 
each EU Member State. 2007–13
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Source: Royal Society, UK research and the European Union The role of the EU in funding UK research 
(December 2015): https://royalsociety.org/~/media/policy/projects/eu-uk-funding/uk-membership-of-eu.pdf 
[accessed 17 March 2016]
